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ABSTRACT 
 
 Reactive intermediates play an important the within the realm of chemical synthesis. 
Their high energy and transient nature make them difficult to observe and characterize, 
but it is these same properties that empower them to form bonds traditionally seen as 
difficult to prepare and unusual architectures quickly and efficiently. Herein, two reactive 
intermediates, arynes and transitient (2azaaryl)-cuprates, are exploited for their abilities 
to prepare important chemical motifs.  Both serve as an avenue into the functionalization 
of arenes to provide products which hold value in a variety of fields including natural 
product total syntethis, pharmaseuticals and ligand design.  
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CHAPTER 1 
The Acyl-Amidation of Arynes 
 
1.1 Introduction 
 
 Arynes have long been of interest to both physical organic and synthetic chemists. 
The structure of benzyne was first elucidated by J. D. Roberts in 1953 and since that time 
a number of methods to generate these reactive intermediates have been realized (Scheme 
1.1).1  Many of these procedures require high temperature or strong base such as n-
butyllithium or sodium amide.2  In 1983, Kobayashi and co-workers reported the in situ 
generation of arynes from corresponding o-silyl aryl triflates.3  This has proven to be one 
of the mildest and most synthetically useful ways of generating arynes.  Desilylation 
upon treatment of the o-silyl aryl triflate with fluoride ion induces an elimination of the 
triflate to furnish the highly strained triple bond characteristic of arynes.  This method 
can be performed under ambient conditions and with a wide variety of fluoride sources.  
While these intermediates cannot be isolated and are difficult to observe 
Chapter 1 – The Acyl Amidation of Arynes 
 
 
 
2 
spectroscopically, they can be harnessed in a variety of reaction pathways to afford 
interesting and important architectures, often forming multiple carbon–carbon or carbon–
heteroatom bonds in a single operation (Scheme 1.2).4   
 
Scheme 1.1. In situ generation of benzyne. 
 
 
 
 
Scheme 1.2.  Representative reactions of benzyne (1). 
 
 
‘ 
The Stoltz group has been interested in the synthetic utility of arynes for a number 
of years. In 2005, Tambar and Stoltz reported on the first acyl alkylation of arynes using 
β-ketoesters (Scheme 1.3).5  Aryne insertion into the alpha, beta carbon–carbon bond of 
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β-ketoesters is thought to proceed through a formal [2+2] cycloaddition followed by 
fragmentation to afford acyl-alkylated products 5–10 in good yield.  Since the Stoltz 
group’s initial studies, aryne insertion into carbon–carbon bonds bearing electron 
withdrawing groups has been extended to a variety of substrate classes, including 1,3-
diketones, 6  α-ketonitriles, 7  β-ketophosphonates, 8  and trifluoromethyl ketones, 9  among 
others (Scheme 1.3).10 More recently, the Garg lab developed a procedure for embedding 
heteroarenes into cyclic ureas in order to probe the inherent regioselectivity of such 
reactions.11 
 
Scheme 1.3. The direct acyl alkylation of arynes. 
 
 
 
 
Scheme 1.4. Insertion of arynes into C–C σ bonds. 
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Previous work by the Greaney group demonstrated that the insertion of amides 
into arynes could afford similar acyl-aminated products (Scheme 1.5).12  However, the 
scope of their method was focused on N-aryl benzamides substrates (12), which 
significantly limited further derivatization of the insertion products (13). These N-aryl 
ortho-acyl anilines (13) could be reacted further to prepare tricyclic polyaromatic 
systems, namely acridines (14) and acridones (15).  We sought to address this limitation 
by developing a method of the insertion of arynes into the C–N bonds of imides (16) 
(Scheme 1.6).  These N-acyl anilines (17) would be far more amenable to derivation 
therefore provide access to an array of important chemical motifs, such as indoles, 
quinolones and ortho-acyl anilines.   
 
Scheme 1.5. Greaney’s Acyl-Amination and Derivatives. 
  
Scheme 1.6. Acyl-Amidation of Arynes. 
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1.2 Acyl-Amidation of Arynes 
 
We initiated our synthetic studies by optimizing conditions for the insertion 
reaction. Using acetylacetamide (16) as a model imide substrate and ortho-silylaryl 
triflate 2 as the aryne precursor, we observed the best yields for the insertion reaction in 
toluene at 60 °C and TBAT as a fluoride source (Table 1.1). 
With optimized parameters in hand, we next set out to explore the substrate scope. 
Our method showed tolerance to imide substrates possessing both aliphatic and aromatic 
substituents, with yields ranging from modest to very good.  Substrates bearing 
carbamate functionalities were also compatible, albeit with reduced yields (entries 7 and 
8). 
 
Table 1.1. Scope of the Imide. 
 
  Having explored the substrate scope of this reaction with respect to the imide, we 
next investigated its tolerance with respect to the aryne precursor used (Table 1.2). 
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Although substituted phenyl ring systems provided fair to good yields, precursors bearing 
nitrogen (i.e. indolyne and pyridyne) fared poorly. 
 
Table 1.2. Substituted Aryne Precursors.  
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Following previous research conducted by the Buchwald group, 13  we found that 
acylamide insertion products could be elaborated to substituted quinolone products by a 
base-initiated Camps cyclization in a two-step, one-pot sequence (see Table 1.3). 
Additionally, these aryl ketoamides have previously been converted to indoles via 
McMurry couplings. N-deacylation of these ketoamides affords ketoanilines. Similarly, 
ketoester insertion products can be elaborated to chromones via base-initiated cyclization 
followed by condensation (Scheme 1.7). or to 1,3 diketones through Baker–
Venkataraman rearrangements. 14  Our lab is making on-going efforts to explore the 
scope of this reaction and its potential in developing other valuable synthetic 
transformations. 
 
Table 1.3. Camps Cyclization of Ketoamide Insertion Products. 
 
 
Scheme 1.7. Derivatization of ortho-acyl anilides. 
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1.3 Conclusion 
 
To summarize, we have discovered a method for inserting arenes into C–N and C–O σ 
bonds of imides and anhydrides, respectively to generate 1,2-ketoamide and ketoester 
products. These compounds are capable of further derivatization to provide a broad array 
of synthetically useful compounds. Our lab is making ongoing efforts to explore the 
scope of this reaction and its potential in developing other valuable synthetic 
transformations. 
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1.4 Experimental Procedures 
 
1.4.1 Materials and Methods.   
 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
nitrogen atmosphere using dry, deoxygenated solvents (distilled or passed over a column 
of activated alumina). Reaction temperatures were controlled by an IKAmag temperature 
modulator.  Thin layer chromatography (TLC) was performed using E. Merck silica gel 
60 F254 precoated plates (0.25 mm) and visualized by UV fluorescence quenching. 
SiliaFlash P60 Academic Silica gel (particle size 0.040-0.063 mm) was used for flash 
chromatography. 1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 
MHz and 125 MHz, respectively) and are reported relative to Me4Si (δ	  0.0). IR spectra 
were recorded on a Perkin Elmer Paragon 1000 Spectrometer and are reported in 
frequency of absorption (cm-1). HRMS were acquired using an Agilent 6200 Series TOF 
with an Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric 
pressure chemical ionization (APCI) or mixed (MM) ionization mode. 
 
1.4.2 Representative Procedure for Acyl-amidation 
 A 2-dram vial equipped with a magnetic stir bar was charged with TBAT and 
acetylacetamide. The vial was purged with nitrogen, and PhMe was added via syringe 
followed by silylaryltriflate. The vial was sealed and placed in an aluminum block 
preheated to 60 oC. The reaction mixture was stirred at this temperature for 16 h, then it 
was allowed to cool to 23 oC. The mixture was concentrated in vacuo and purified by 
column chromatography (10% EtOAc in hexanes) to afford a white solid. 
Characterization data match those previously reported. 
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1.4.3 Spectroscopic Data 
 
The spectroscopic data for compounds 18-1,15 18-4,15 19-1,16 19-2,17 19-10, 30,18 32,19 
3318 were identical to those previously reported. 
  
 
N-propionylpropionamide (18-2) 
1H NMR (500 MHz, CDCl3) δ 7.73 (s, 1H), 2.62 (q, J = 7.4 Hz, 3H), 1.18 (t, J = 7.4 Hz, 
4H); 13C NMR (126 MHz, CDCl3) δ 175.17, 30.87, 8.52; IR (NaCl/Film) 3266.83, 
3175.24,2978.35, 1736.17, 1503.45, 1421.79, 1181.11, 1072.97, 729.68 cm–1; HRMS  
 
 
Di-1-adamantanecarboxamide (18-3) 
1H NMR (500 MHz, CDCl3) δ 2.04 (dd, J = 7.4, 2.6 Hz, 6H), 1.93 (d, J = 2.9 Hz, 12H), 
1.73 (m, 12H); IR (NaCl/Film) 2906.06, 2851.48, 1693.63, 1453.93, 1325.17, 1284.81, 
1250.94, 1102.93, 952.74, 743.88.   
 
 
3-methyl-N-(3-methylbutanoyl)butanamide (18-6)  
1H NMR (300 MHz, CDCl3) δ 8.72 (br s, 1H), 2.47 (d, J = , 4H), 2.14 (heptet, J = , 2H); 
13C (125 MHz, CDCl3) δ 173.9, 46.3, 25.2, 22.4; IR (NaCl/Film); HRMS (MM: ESI-
APCI) m/z calc’d for C10H19NO2 [M+H]+ = 186.1494, found 186.1500. 
Me
N
H
O O
Me
N
H
O O
MeO
N
H
Me
OMe
Me
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3-phenyl-N-(3-phenylpropanoyl)propanamide (18-9) 
1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.25 (m, 10H), 2.95 (m, 8H); 13C NMR (126 
MHz, CDCl3) δ 173.09, 140.33, 128.71, 128.54, 126.52, 39.20, 30.39; IR (NaCl/Film) 
3147.72, 1675.04, 1494.86, 1453.56, 1380.88, 1311.33, 1199.44, 1146.83, 981.74, 
725.51, 697.04 cm–1; (MM: ESI-APCI) m/z calc’d for C18H19NO2 [M+H]+ = 282.1489, 
found 282.1489. 
 
 
N-(2-isobutyrylphenyl)isobutyramide (19-5) 
1H NMR (300 MHz, CDCl3) δ 11.80 (br s, 1H), 8.79 (d, J = 6 Hz, 1H), 7.93 (d, J = 6 Hz, 
1H), 7.53 (t, J = 4.5 Hz, 1H), 7.10 (t, J = 6 Hz, 1H), 3.65 (sept, J = 6 Hz, 1H), 2.62 (sept, 
J = 6 Hz, 1H), 1.28 (d, J = 6 Hz, 6H), 1.22; 13C (75 MHz, CDCl3) δ 209.2, 176.6, 141.7, 
134.8, 130.6, 122.2, 121.1, 120.7, 37.6, 36.3, 19.6 (2 unresolved signals); IR (Neat Film, 
NaCl); HRMS (MM: ESI-APCI) m/z calc’d for C14H19NO2 [M+H]+ = 234.1489 , found 
234.1490. 
 
N
H
O O
Me
Me
O
NH
Me
Me
O
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3-methyl-N-(2-(3-methylbutanoyl)phenyl)butanamide (19-6)  
1H NMR (300 MHz) δ 11.73 (br s, 1H), 8.77 (d, J = , 1H), 7.90 (d, J = , 1H), 7.53 (t, J = , 
1H), 7.10 (t, J = , 1H), 2.88 (d, J = , 2H), 2.33–2.19 (m, 4H), 1.03–0.99 (m, 12H); 13C 
(126 MHz) 205.0, 172.1, 141.0, 134.9, 130.4, 122.2, 121.92, 120.9, 49.0, 48.1, 26.3, 25.6, 
22.7, 22.5. IR (Neat Film, NaCl); HRMS (MM: ESI-APCI) m/z calc’d for C16H23NO2 
[M+H]+ = 262.1802 , found 262.1804. 
 
 
3-phenyl-N-(2-(3-phenylpropanoyl)phenyl)propanamide (19-9) 
Observed as rotomers, major rotomer reported. 1H NMR (500 MHz, CDCl3) δ 11.71 (s, 
1H), 8.76 (dd, J = 8.5, 1.1 Hz, 1H), 7.89 (dd, J = 8.2, 1.5 Hz, 1H), 7.55 (m, 1H), 7.40 (m, 
1H), 7.26 (m, 10H), 3.35 (m, 2H), 3.09 (m, 2H), 3.03 (dd, J = 8.4, 7.1 Hz, 2H); IR 
(NaCl/Film) 3026.46, 2925.93, 1696.65, 1651.11, 1604.35, 1583.56, 1519.16, 1450.30, 
1360.55, 1297.79, 1194.79, 1194.90, 976.10, 751.87, 698.56 cm–1; HRMS (MM: ESI-
APCI) m/z calc’d for C24H23NO2 [M+H]+ = 358.1802, found 358.1812. 
  
O
NH
O
Me
Me
Me
Me
O
NH
O
Ph
Ph
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N-(2-acetyl-4,5-dimethylphenyl)acetamide (22) 
1H NMR (300 MHz, CDCl3) δ 11.63 (br s, 1H), 8.53 (s, 1H), 7.61 (s, 1H), 2.63 (s, 3H), 
2.31 (s, 3H), 2.26 (s, 3H), 2.21 (s, 3H); 13C (75 MHz, CDCl3) δ 202.4 (C), 169.4 (C), 
145.3, 139.1 (C), 132.4 (CH), 130.6 (C), 121.5 (CH), 119.8 (C), 28.6 (CH3), 25.6 (CH3), 
20.6 (CH3), 19.4 (CH3); IR (Neat Film/NaCl); HRMS (MM: ESI-APCI) m/z calc’d for 
C12H15NO2 [M+H]+  = 206.1176, found 206.1171. 
 
 
N-(3-acetylnaphthalen-2-yl)acetamide (24) 
1H NMR (300 MHz, CDCl3) δ 11.5 (br s, 1H), 9.12, (s, 1H), 8.44 (s, 1H), 7.83 (d, J = 9.0 
Hz, 2H), 7.57 (t, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 2.80 (s, 3H), 2.27 (s, 3H); 13C 
(75 MHz, CDCl3) 203.0 (C), 169.3 (C), 136.7 (C), 136.1 (C), 134.3 (CH), 129.7 (CH), 
128.9 (CH), 128.2 (C), 127.7 (CH), 125.6 (CH), 122.7 (C), 117.7 (CH), 28.7 (CH3), 25.6 
(CH3). IR (Neat Film, NaCl); HRMS (MM: ESI-APCI) m/z calc’d for C14H13NO2 
[M+H]+ = 228.1019, found 228.1022. 
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NHMe
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N-(6-acetylbenzo[d][1,3]dioxol-5-yl)acetamide (26) 
1H NMR (300 MHz, CDCl3) δ 12.08 (br s, 1H),  8.37 (s, 1H), 7.25 (s, 1H), 6.02 (s, 2H), 
2.57 (s, 3H), 2.20 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 200.6 (C), 169.5 (C), 152.9 (C), 
142.4 (C), 139.3 (C), 115.1 (C), 109.6 (CH), 102.1 (CH), 101.5 (CH2), 28.8 (CH3), 25.6 
(CH3). IR (Neat Film, NaCl); HRMS (MM: ESI-APCI) m/z calc’d for C11H11NO4 
[M+H]+ = 222.0761, found 222.0766. 
 
 
 
N-(2-acetyl-3-methoxyphenyl)acetamide (30) 
1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.40 (td, J = 8.4, 
0.5 Hz, 1H), 6.69 (dd, J = 8.4, 0.9 Hz, 1H), 3.90 (s, 3H), 2.61 (s, 3H), 2.17 (s, 3H); 13C 
NMR (126 MHz, cdcl3) δ 204.58, 169.20, 160.00, 139.40, 133.90, 114.14, 106.31, 55.83, 
33.73, 25.48; IR (NaCl/Film) 3086.81, 2947.73, 1698.62, 1639.62, 1634.03, 1528.84, 
1470.57, 1470.57, 1403.54, 1273.11, 1243.38, 1195.89, 1093.22, 1017.32, 967.43, 
802.27, 735.19, 610.77 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H13NO3 
[M+H]+ = 262.1802 , found 262.1804. 
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 13C NMR (126 MHz, CDCl3) of compound 18-2. 
 
Infrared spectrum (Thin Film, NaCl) of compound 18-2. 
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 13C NMR (126 MHz, CDCl3) of compound 18-3. 
 
Infrared spectrum (Thin Film, NaCl) of compound 18-3. 
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 13C NMR (126 MHz, CDCl3) of compound 18-6. 
 
Infrared spectrum (Thin Film, NaCl) of compound 18-6. 
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 13C NMR (126 MHz, CDCl3) of compound 18-6. 
 
Infrared spectrum (Thin Film, NaCl) of compound 18-9. 
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 13C NMR (126 MHz, CDCl3) of compound 19-6. 
 
Infrared spectrum (Thin Film, NaCl) of compound 19-6. 
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 13C NMR (126 MHz, CDCl3) of compound 19-6. 
 
Infrared spectrum (Thin Film, NaCl) of compound 19-6. 
 
Appendix 1 – Spectra Relevant to Chapter 1 
 
 
30 
0
1
2
3
4
5
6
7
8
9
10
11
12
pp
m
  
 1 H
 N
M
R
 (3
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
22
. 
 
 
22
M
e
O
NH
M
e
M
e
O
M
e
Appendix 1 – Spectra Relevant to Chapter 1 
 
 
31 
020406080100120140160180200
ppm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (126 MHz, CDCl3) of compound 22. 
 
Infrared spectrum (Thin Film, NaCl) of compound 22. 
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 13C NMR (126 MHz, CDCl3) of compound 24. 
 
Infrared spectrum (Thin Film, NaCl) of compound 24. 
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 13C NMR (126 MHz, CDCl3) of compound 26. 
 
Infrared spectrum (Thin Film, NaCl) of compound 26. 
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 13C NMR (126 MHz, CDCl3) of compound 3g. 
 
Infrared spectrum (Thin Film, NaCl) of compound 3g. 
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CHAPTER 2 
Progress Toward the Total Synthesis of Jorumycin 
 
2.1 Introduction 
Over the past decades, the tetrahydroisoquinoline (THIQ) alkaloids have piqued 
the attention of medicinal, biological, and chemical communities due to their novel 
biochemical modes of action, the potent biological properties they exhibit, and the 
complex molecular architectures characteristic of these molecules (Figure 1).1  With more 
than 60 naturally occurring representatives, this family of compounds boasts a 
remarkable degree of structural diversity that translates into a wide array of 
antineoplastic/antiproliferative properties.  For example, jorumycin (50) inhibits the 
growth of A549 human lung carcinoma and HT29 human colon carcinoma cell lines at 
extremely low concentrations (IC50 = 0.24 nM).2  Saframycins A (51) and S (52) display 
nanomolar cytotoxicity toward L1210 leukemia cell lines (IC50 = 5.6, 5.3 nM, 
respectively). The therapeutic potential of these molecules is perhaps best conveyed by 
those members that have advanced through human clinical trials.  Ecteinascidin 743 
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(Trabectedin, Yondelis, 53) is approved in Europe, Russia, and South Korea for the 
treatment of soft tissue sarcomas and has been granted priority review by the FDA within 
the U.S. as a treatment for patients with advanced soft tissue sarcoma (STS), including 
liposarcoma and leiomyosarcoma subtypes, and phase III trials were recently completed.3, 
4a  In addition to their various antineoplastic properties, the THIQ alkaloids also possess 
broad-spectrum antibiotic activity against the Gram-positive and Gram-negative bacterial 
strains responsible for infectious diseases such as meningitis, pneumonia, strep throat, 
and diphtheria.5  
 
Figure 2.1. Tetrahydroisoquinoline natural products. 
 
While the numerous biological properties of the THIQ alkaloids make them ideal 
targets for pharmaceutical development, the isolation of material from natural sources is 
often expensive and low yielding.1  Fortunately, in such cases, chemical synthesis can 
provide an alternative means to produce the quantities necessary for advanced biological 
testing.  It is therefore of critical to develop synthetic methods that assemble these 
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important molecules in a concise and efficient manner. In 2010, we published on the total 
synthesis of quinocarcin (54), a mono-THIQ, and have recently turned our attention to 
the preparation of the related bis-THIQ alkaloids.  In pursuit of this goal, we devised a 
general technique to rapidly construct the core of the THIQ alkaloids while providing 
avenues to introduce the varying peripheral functionality that make up this large and 
diverse class of natural products.  
As the first such molecule to investigate, we selected jorumycin (50), a bioactive 
isolate from the sea slug Jorunna funebris.6,7 Taking into account the fundamental 
structural features that jorumycin (50) shares with other members of the class of bis-
THIQ natural products containing the potent saframycins, safracins, renieramycins and 
cribrostatins, we believe that jorumycin will serve as the cornerstone for a general, 
convergent, and concise strategy to its relatives. 2, 8, 9 
Herein, we have devised a synthetic route, which obviates such a need.  Instead, 
our route to jorumycin hinges on a diastereoselective reduction of a bis-
tetrahydroisoquinoline, which itself can be prepared from a highly convergent cross-
coupling of two isoquinoline subunits.  
 
2.2 Retrosynthetic Analysis of Jorumycin 
Retrosynthetically, we envisioned that the pentacyclic bis-THIQ core of jorumycin 
(50) could be accessed by late-stage assembly of the central C-ring piperazine.  
Consequently, we are targeted bis-THIQ 55, which could undergo cyclization to form the 
pentacyclic core of jorumycin.  To construct this intermediate, we planned to reduce bis-
isoquinoline 56 by a diastereoselective tetra-hydrogenative pathway.  We believed that 
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this bis-isoquinoline could furnished by an Csp2–H/Csp2–OTf cross-coupling of two 
component isoquinolines (57 and 58), each of which could be prepared by methods 
previously developed in our laboratories from a single aryne precursor 59.10  This highly 
modular approach distinguishes itself from previous syntheses by convergently 
generating the carbon framework of the bis-THIQ alkaloids in a regio- and 
stereoselective manner without the use of one or more Pictet-Spengler reactions in a 
linear sequence.1  Strategies utilizing the Pictet-Spengler reaction necessitate the use of 
electron-rich arenes.  Our approach eliminates this need and allows one to envision 
access to an array of THIQ analogs, simply by varying the aryne precursor.  
 
Scheme 2.1. Retrosynthetic Analysis of Jorumycin. 
 
 
2.3 Synthesis of Jorumycin 
We began our synthesis of jorumycin by looking to prepare isoquinolines 57 and 
58 (Scheme 2.2). Our lab has developed two methods for the regioselective synthesis of 
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highly substituted isoquinolines.10 The N-oxide coupling partner 57 was attained through 
the annulation of silyl aryl triflate 58 with methyl 2-formamidoacrylate (60).  Subsequent 
oxidation using mCPBA affords the Csp2–H coupling partner 57. We next turned our 
attention to 3-isoquinoline triflate 58. Acyl-alkylation of the same silyl aryl triflate 58 
was accomplised upon exposure to KF and methyl acetoacetate (62). Subsequent 
condensation with ammonium hydroxide furnished 3-hydroxy isoquinoline 63, which 
was quantitatively triflated using triflic anhydride to afford our desired isoquinoline 
Csp2–OTf coupling partner (58).  
 
Scheme 2.2. Preparation of isoquinolines 57 and 58.  
 
 
We next examined the convergent coupling of the two isoquinoline fragments. To 
this end, we investigated Pd-catalyzed oxidative coupling reactions, originally reported 
by Fagnou, that enable the coupling of aryl halides and heterocyclic N-oxides by C–H 
functionalization. 11   In the event, isoquinoline N-oxide 57 and triflate 58 were 
successfully coupled to furnish bis-isoquinoline 64 using modified Fagnou conditions 
(Scheme 2.3).  
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Scheme 2.3. Cross-coupling of isoquinolines 57 and 58.  
 
While the cross-coupling of our two isoquinoline quinolone fragments represents 
a highly convergent route to the bis-THIQ, the scalablity of our aryne annulation reaction 
to prepare isoquinoline ester 61 was not ideal (22% yield from 59 to 57) and led us to 
devise an alternative route to bis-isoquinoline 64. While methyl 2-formamidoacrylate 
(65) proved to be a difficult substrate for our aryne annulation methodology, methyl 2-
acetamidoacrylate (65) has been a robust annulation partner. We therefore pursued a 
sequence in which aryne annulation, saponification and amide formation furnishes serine 
derivative 67 (Scheme 2.4). Dehydration affords amidoacrylate 68, which we can use in a 
second regio-selective aryne annulation reaction thus providing bis-isoquinoline 64. 
While this route provides a similar overall yield to the cross-coupling strategy, it has 
proven to be more scalable, providing greater quantities of bis-isoquinoline 64.  
With a robust method for the preparation of bis-isoquinoline 64 available, we 
turned our attention to the latter steps of the synthesis, namely oxidation of C(22), 
tetrahydrogenation of the bis-isoquinoline core and C-ring formation.  Initially, we found 
that bis-isoquinoline 11 undergoes smooth benzylic oxidation upon treatment with SeO2 
at C(22) and subsequent reduction of the resultant aldehyde to afford the hydroxymethyl 
bis-isoquinoline 7 in 86% yield (Scheme 2.4).  
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Scheme 2.4. Alternative approach to bis-isoquinoline 64.  
 
With bis-isoquinoline 56 in hand, we turned our attention to the key reduction of 
this intermediate.12  After extensive experimentation we discovered that exposure of bis-
isoquinoline 56 to Adams’ catalyst, hydrogen gas, and acetic acid, followed by LiOH-
induced cyclization provides a pentacyclic lactam.  This compound was treated with 
formaldehyde and NaBH3CN to install a CH3 at N(12) with the desired all cis 
stereochemistry (Scheme 2.5).  This allowed for the isolation of THIQ 73 in 21% yield 
overall yield.  Although the isolated yield of THIQ 73 is moderate, it is the only 
characterizable bis-THIQ structure that we have been able to isolate to date.  Given the 
complexity of the tetrahydrogenation reaction, it is remarkable that the process procedes 
with good diastereoselectivity.  We believe this diastereoselectivity is a function of a self-
reinforcing situation, wherein each hydrogenation enhances the stereoselectivity of the 
subsequent event (Scheme 2.5).  
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Scheme 2.5. The Diastereoselective Reduction of Bis-Isoquinoline 56. 
 
With this highly diastereoselective reduction/cyclization sequence, we have 
accessed the core of the bis-THIQ alkaloid natural products in a highly convergent and 
rapid manner in 9 steps from aryne precursor 59. Selective bis-demethylation of 
pentacycle 73 provides bis-phenol 74, which can be advanced to several bis-THIQ 
alkaloids by known sequences of minimal steps.  In the case of jorumycin (1), 4 steps are 
needed for intermediate 74.13 
 
Me
MeO
OMe
56
N
N CO2Me
MeO
MeO
Me
OH
H2 (1 bar)
PtO2, AcOH Me
MeO
OMe
72
NH
N
H
CO2Me
MeO
MeO
Me
OH
1. LiOH, THF/H2O
2. NaBH3CN, CH2O
MeCN/MeOH
(21% yield, 3 steps)
N
N
OMe
Me
MeO
H
Me
MeO
OMe
Me
O
OH
73
N
OMe
MeO
Me
N CO2Me
MeO
MeO
Me
OH
B
D
1
2
3
4
4'
3'
2'
1'
B-ring 
1,2-Reduction
NH
OMe
MeO
Me
N CO2Me
MeO
MeO
Me
OH
B-ring 
3,4-Reduction
NH
OMe
MeO
Me
N CO2Me
MeO
MeO
Me
OH
H D-ring 
Reduction
NH
OMe
MeO
Me
N
H
CO2Me
MeO
MeO
Me
OH
H
H
56 70
71 72
13
Chapter 2 – Progress Toward the Total Synthesis of Jorumycin 46 
Scheme 2.6. Completion of the Synthesis of Jorumycin. 
 
 A highly convergent synthesis of (±)-jorumycin has been achieved.  Unlike 
previous syntheses, our approach relies on the convergent cross-coupling of two 
isoquinoline subunits followed by a highly diastereoselective reduction and cyclization 
sequence to access the pentacyclic core, eliminating the need for electron-rich arenes to 
perform electrophilic aromatic substitution reactions.  Our laboratory is currently using 
this strategy to prepare other members of this important class of natural products along 
with non-natural derivatives thereof.  
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2.4 EXPERIMENTAL SECTION 
2.4.1  Materials and Methods 
Unless stated otherwise, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents (distilled or passed 
over a column of activated alumina).  Commercially obtained reagents were used as 
received.  Reaction temperatures were controlled by an IKAmag temperature modulator.  
Thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 F254 
precoated plates (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, or CAM staining.  SiliaFlash P60 Academic Silica gel (particle size 
0.040-0.063 mm) was used for flash chromatography.  1H and 13C NMR spectra were 
recorded on a Varian 500 (at 500 MHz and 125 MHz, respectively) and are reported 
relative to CHCl3 (δ 7.24).  Data for 1H NMR spectra are reported as follows: chemical 
shift (δ ppm) (multiplicity, coupling constant (Hz), integration).  Data for 13C spectra are 
reported in terms of chemical shift relative to CHCl3 (δ 77.23).  IR spectra were recorded 
on a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of 
absorption (cm–1). HRMS were acquired using an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric 
pressure chemical ionization (APCI) or mixed (MM) ionization mode. 
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2.4.2  Preparative Procedures Spectroscopic Data 
 
 
3-Bromovanillin (A2-2) 
The following procedure was adopted from a literature report by Rao and 
Stuber.14 A single-neck, 2 L round-bottom flask was charged with vanillin (A2-1, 50 g, 
328.6 mmol).  Glacial acetic acid was added (1.1 L, 3.0 M).  Following this, a mechanical 
stirrer was affixed to the flask through the neck and, with vigorous but even stirring, the 
vanillin dissolved to form a pale yellow solution.  At this point, neat bromine (16.84 mL, 
361.5 mmol) was added in a rapid dropwise fashion to the stirring solution through the 
flask neck to produce a deep red-orange solution.  Following addition, the reaction was 
maintained with vigorous stirring for 90 minutes, after which time TLC analysis 
indicated formation of the product (Rf = 0.32, 15% ethyl acetate in hexanes).  The 
reaction also results in the formation of a bright orange-yellow precipitate when nearing 
completion. Upon completion of the reaction, the mechanical stirrer was disengaged and 
the contents of the reaction flask were poured onto chilled deionized water (0 °C, 600 
mL), resulting in further precipitation of a pale yellow solid from the bright orange 
aqueous layer.  The reaction flask was washed into this flask with more chilled water.  
While still cooled, the contents of the 1 L Erlenmeyer flask were filtered over a glass frit 
to separate the desired solid product.  The isolated solid product (A2-2, 75.25 g, 99% 
yield) was transferred to a flask and dried under vacuum for a period of 8 hours 
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. 
 
3-bromo-4,5-dimethoxy benzaldehyde (A2-3) 
To a 1 L round-bottom flask was added anhydrous K2CO3 (113.56 g, 821.6 
mmol), followed by a solution of bromobenzaldehyde A2-2 (75.25 g, 325.66 mmol) in 
reagent grade acetone (700 mL).  A mechanical stirrer was affixed to the reaction flask, 
and vigorous stirring was required to generate an evenly distributed, maroon suspension.  
To this stirring mixture was added Me2SO4 (77.74 mL, 821.69 mmol) over 1 minute via 
funnel.  The reaction was left to stir vigorously at 25 °C for 8 hours, at which point TLC 
analysis confirmed the conversion of phenol A2-2 to a less polar product.  The reaction 
contents were then vacuum filtered over a glass frit to separate residual solid K2CO3.  The 
filtered solid was washed with acetone (2 x 100 mL) and methanol (100 mL).  The 
organic filtrate was concentrated to an orange oil and purified by flash chromatography 
(5% ! 50% ethyl acetate in hexanes eluent) to yield bromobenzaldehyde A2-3 (76.6 g, 
96% yield), which was isolated as a white powder: Rf = 0.56 (30% ethyl acetate in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 9.86 (s, 1H), 7.67 (d, J = 1.80 Hz, 1H), 7.40 (d, 
J = 1.85 Hz, 1H), 3.96 (s, 3H), 3.95 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 189.83, 
154.17, 151.81, 133.03, 128.77, 117.92, 110.09, 60.83, 56.25; IR (NaCl/film) 2945, 2860, 
1692, 1588, 1566, 1486, 1469, 1452, 1420, 1393, 1380, 1312, 1281, 1240, 1212, 1144, 
1133, 1048, 993, 855, 840 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C9H9BrO3 [M]+: 
243.9735, found 243.9731. 
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3,4-dimethoxy-5-methylbenzaldehyde (A2-4) 
A 250 mL round-bottom flask was charged with lithium chloride (4.32 g, 102.00 
mmol) and then flame dried.  To this flask was added a solution of benzaldehyde A2-3 
(5.0 g, 20.40 mmol) in N,N-dimethylformamide (200 mL) that had been rigorously 
sparged with argon.  Next, PdCl2(PPh3)2 (0.358 g, 0.51 mmol) was added to the stirring 
mixture, producing a bright yellow-orange solution that was stirred vigorously.  A reflux 
condenser was affixed to the top of the reaction flask before adding, dropwise, neat 
tetramethyltin (7.06 mL, 51.0 mmol).  The reaction vessel was sealed under an argon 
atmosphere and heated to reflux in 100 °C oil bath.  The reaction was maintained at 
reflux for 3 hours; during this period the color of the solution changed to dark red-
orange.15  TLC analysis of the reaction after this period showed full consumption of the 
starting material.  The reaction was cooled to room temperature and then quenched by the 
addition of H2O (200 mL).  The aqueous layer was thoroughly extracted with ethyl 
acetate (5 x 200 mL), and the combined organic layers were washed with brine (150 mL).  
The organic extract was dried over MgSO4, concentrated under vacuum, and purified by 
flash chromatography (5% ethyl acetate in hexanes eluent) to furnish benzaldehyde A2-4 
as a colorless oil (3.63 g, 99% yield): Rf = 0.42  (10% ethyl acetate in hexanes); 1H NMR 
(500 MHz, CDCl3) δ 9.85 (s, 1H), 7.17 (d, J = 1.71 Hz, 1H), 7.16 (d, J = 0.60 Hz, 1H), 
3.78 (s, 3H), 3.77 (s, 3H), 2.19 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 191.14, 153.02, 
H
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152.70, 126.95, 108.79, 60.05, 55.65, 15.75; IR (NaCl/film) 2939, 2833, 1693, 1586, 
1491, 1465, 1422, 1387, 1329, 1299, 1233, 1140, 1096, 1003, 856 cm–1; HRMS (MM: 
ESI-APCI) m/z calc’d for C10H12O3 [M]+: 180.0786, found 180.0779. 
 
 
3,4-dimethoxy-5-methylphenol (A2-5) 
A 250 mL round-bottom flask was charged with anhydrous NaHCO3 (0.467 g, 
0.56 mmol).  To this, was added a solution of benzaldehyde A2-4 (1.00 g, 5.55 mmol) in 
CH2Cl2 (11 mL).  This mixture was vigorously stirred until the NaHCO3 fully dissolved.  
At this point, m-CPBA (1.92 g, 11.10 mmol) was added as a solid in a single portion to 
the pale yellow solution.  Immediately, the solution turned bright yellow, and was 
maintained with stirring at 25 °C under an atmosphere of N2.  Notable accumulation of 
precipitate resulted in increasing turbidity of the solution, and after 6 hours, TLC analysis 
indicated formation of a new product (Rf = 0.22, hexanes) and consumption of 
benzaldehyde A2-4.  At this time, methanol (110 mL) and anhydrous K2CO3 (2.30 g, 
16.65 mmol) were added, and the solution turned maroon in color.  The reaction was 
maintained at 25 °C for 12 hours, resulting in formation of a new polar product.  The 
reaction was stopped by concentration under vacuum to yield a dark maroon solid.  This 
solid was dissolved in H2O (100 mL), and then neutralized with concentrated aqueous 
HCl (6 mL).  Warning: vigorous gas evolution.  The resulting suspension was extracted 
with CH2Cl2 (5 x 100 mL), and the combined organic extracts were washed with 
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saturated aqueous NaHCO3 (2 x 200 mL) to remove benzoate byproducts.  The organic 
layers were dried with Na2SO4, concentrated under vacuum, and purified by flash 
chromatography (30% ethyl acetate in hexanes eluent) to provide phenol A2-5 (0.822 g, 
4.89 mmol, 88% yield) as a white solid: Rf = 0.30 (30% ethyl acetate in hexanes); 1H 
NMR (500 MHz, CDCl3) δ 6.29 (d, J = 2.80 Hz, 1H), 6.20 (d, J = 2.80 Hz, 1H), 4.53 (s, 
1H), 3.81 (s, 3H), 3.73 (s, 3H), 2.21 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 153.36, 
151.78, 141.12, 132.41, 108.36, 98.17, 60.35, 55.69, 15.85; IR (NaCl/film) 3272, 2957, 
1614, 1483, 1463, 1440, 1430, 1348, 1268, 1226, 1219, 1196, 1181, 1154, 1096, 1001, 
854, 772, 737 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C9H12O3 [M]+: 168.0786, 
found 168.0753. 
 
 
Isopropyl carbamate A2-6 
This procedure was adopted from the literature procedure reported by Bronner, et 
al.16 A 100 mL round-bottom flask was charged with a solution of phenol A2-5 (1.696 g, 
10.08 mmol) in CH2Cl2 (35 mL).  The solution was stirred at 25 °C under an atmosphere 
of N2 before neat isopropyl isocyanate (1.483 mL, 15.12 mmol) was added via syringe.  
The solution turned orange, and after 5 minutes of stirring, freshly distilled Et3N (0.281 
mL, 2.02 mmol) was added via syringe to effect the formation of a dark purple solution.  
The reaction was maintained with stirring for 18 hours at 25 °C.  Following this period, 
TLC analysis showed conversion of phenol A2-5 to a single product.  The reaction was 
Me
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(99% yield)
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concentrated to an orange-brown residue and purified by flash chromatography (5% ethyl 
acetate in hexanes eluent) to provide isopropyl carbamate A2-6 as a clear, pale yellow oil 
(2.553 g, 10.08 mmol, 99% yield): Rf = 0.48 (30% ethyl acetate in hexanes); 1H NMR 
(500 MHz, CDCl3) δ 6.55 (d, J = 2.65 Hz, 1H), 6.54 (d, J = 2.65 Hz, 1H), 2.79 (s, 1H), 
3.87 (m, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 2.24 (s, 3H), 1.23 (d, J = 7.25 Hz, 6H); 13C NMR 
(125 MHz, CDCl3) δ 153.92, 152.87, 146.66, 144.62, 115.29, 104.21, 60.15, 55.78, 
43.44, 22.93, 15.91; IR (NaCl/film) 3326, 2972, 2936, 1715, 1604, 1529, 1490, 1466, 
1422, 1332, 1220, 1190, 1175, 1142, 1095, 1050, 1009, 936, 854, 773 cm–1; HRMS 
(MM: ESI-APCI) m/z calc’d for C13H19NO4 [M]+: 253.1314, found 253.1319. 
 
 
TMS carbamate A2-7 
This procedure was adopted from the literature procedure reported by Bronner, et 
al.3 To a solution of isopropyl carbamate A2-6 (9.10 g, 35.9 mmol) in diethyl ether (180 
mL) was added freshly distilled TMEDA (5.90 mL, 39.5 mmol).  The solution was 
cooled to 0 °C. Distilled TBSOTf (9.00 mL, 39.5 mmol) was then added.  The resulting 
solution was maintained for 10 minutes at 0 °C and then the flask was allowed to warm to 
23 °C over 30 minutes. Additional TMEDA was then added to the mixture (21.5 mL, 144 
mmol).  The reaction was then cooled to –78 °C with vigorous stirring to avoid 
aggregation of triflate salts.  Next, n-BuLi (2.5 M in hexanes, 58.0 mL, 144 mmol) was 
added dropwise.  The solution was maintained with stirring at –78 °C for 4 hours, after 
which time freshly distilled TMSCl (32.0 mL, 251 mmol) was added dropwise.  The 
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reaction vessel was allowed to warm to 23 °C over the course of two hours.  At this point, 
TLC analysis indicated the presence of a single, new product.  Saturated aqueous 
NaHSO4 solution (150 mL) was added and stirred with the reaction mixture for 0.5 hour.  
The layers were separated and the organic layer was washed with an additional 150 mL 
of the NaHSO4 solution.  The combined aqueous layers were then extracted with diethyl 
ether (3 x 250mL).  The combined organic extracts were washed with brine (250 mL), 
dried with Na2SO4, and then concentrated under vacuum to a colorless crystalline solid.  
Purification via flash chromatography (5% → 15% ethyl acetate in hexanes eluent) 
provided pure TMS carbamate A2-7 (11.6 g, 99% yield): Rf = 0.63 (15% ethyl acetate in 
hexanes); 1H NMR (500 MHz, CDCl3) δ 6.62 (s, 1H),  4.69 (d, J = 7.08 Hz, 1H), 3.89 (m, 
1H), 3.83 (s, 3H), 3.76 (s, 3H), 2.23 (s, 3H), 1.23 (d, J = 6.75, 6H), 0.29 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 156.69, 153.00, 149.33, 147.28, 133.33, 121.79, 118.88, 
59.19, 58.54, 42.27, 21.88, 14.83, 0.13; IR (NaCl/film) 3326, 2971, 2937, 1710, 1601, 
1530, 1464, 1384, 1370, 1324, 1247, 1220, 1193, 1179, 1080, 1026, 987, 844, 810, 759 
cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C16H27NO4Si [M+H]+: 326.1734, found 
326.1725. 
 
 
Silyl aryl triflate A2-8 
To a solution of TMS carbamate A2-7 (13.2 g, 40.5 mmol) in THF (160 mL) at – 78 °C 
was added diethylamine (6.30 mL, 60.8 mmol), followed by n-BuLi (2.5 M in hexanes, 
24.3 mL, 60.8 mmol). After 20 minutes, the reaction was allowed to warm to 23 °C for 
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30 minutes. PhNTf2 (21.7 g, 60.8 mmol) was then added in one portion.  The reaction 
was maintained with stirring for 4 hours at 23 °C, after which point more diethylamine 
was added (7.50 mL, 72.9 mmol). The reaction was stirred at 23 °C for 12 hours. The 
reaction was then filtered on a silica pad, and washed with 25% EtOAc in hexanes. 
Evaporation of the solvent, followed by purification via flash chromatography (2% ethyl 
acetate in hexanes eluent) yielded silyl aryl triflate A2-8 (14.9 g, 99% yield) as a pale 
yellow oil that crystallize upon cooling: Rf = 0.68 (15% ethyl acetate in hexanes); 1H 
NMR (500 MHz, CDCl3) δ 6.87 (s, 1H), 3.86 (s, 3H), 3.77 (s, 3H), 2.27 (s, 3H), 0.36 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 158.72, 150.74, 149.21, 135.84, 117.49 (q, J = 320 
Hz), 124.53, 117.96, 60.79, 60.03, 16.43, 1.41; 19F NMR (282 MHz, CDCl3) δ –73.10; IR 
(NaCl/film) 2956, 2858, 1600, 1464, 1420, 1383, 1368, 1292, 1248, 1213, 1179, 1142, 
1068, 1023, 982, 930, 873, 846, 764 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for 
C13H19F3O5SSi [M]+: 372.0675, found 372.0674. 
 
 
Ketoester A2-9 
To a solution of silyl aryl triflate 59 (1.86 g, 5.00 mmol) in THF (50 mL) was 
added methyl acetoacetate (62, 0.54 mL, 5.00 mmol), KF (872 mg, 15.0 mmol) and 18-
crown-6 (4.00 g, 15.0 mmol) at 23 °C.  The reaction was maintained at this temperature 
for 16 hours, at which time TLC analysis indicated complete consumption of silyl aryl 
triflate 59. The solution was diluted with diethyl ether (150 mL) and water (150 mL). The 
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aqueous layer was extracted with diethyl ether (3 x 150 mL), and the combined organic 
layers were dried over Na2SO4, filtered and concentrated.  Purification of this residue by 
flash chromatography (10% EtOAc in hexanes eluent) furnished ketoester A2-9 (860 mg, 
65% yield) as a colorless solid: Rf = 0.49 (4:1 hexanes:ethyl acetate) along with the 
corresponding α-arylation bi-product (170 mg, 13% yield, not characterized); 1H NMR 
(500 MHz, CDCl3) δ 6.76 (s, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.66 (s, 3H), 3.60 (s, 2H), 
2.53 (s, 3H), 2.23 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 204.67, 172.20, 150.95, 150.51, 
134.57, 134.26, 128.77, 126.84, 61.37, 60.28, 52.20, 37.96, 32.46, 16.09; IR (NaCl/film) 
2951, 2849, 1740, 1692, 1604, 1568, 1484, 1451, 1437, 1400, 1351, 1306, 1269, 1200, 
1167, 1147, 1078, 1040, 1012 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H10O2N 
[M+H]+: 267.1227, found 267.1233. 
 
 
3-Hydroxyisoquinoline 63 
 Ketoester A2-9 (735 mg, 2.76 mmol) was dissolved in MeCN (2 mL) in a 
pressure flask with a sealable top.  To this was added 28–30% aqueous ammonium 
hydroxide (4 mL), and the flask was sealed.  The reaction was maintained at 60 °C with 
vigorous stirring for 18 hours.  At this point, a yellow solid was generated and TLC 
analysis indicated the complete consumption of the starting material. The reaction 
mixture was then cooled to 23 °C, and the solid was filtered and washed with water. The 
resulting yellow residue was analytically pure 3-hydroxyisoquinoline 63 (324 mg, 1.32 
mmol). The filtrate was diluted with dichloromethane (5 mL), NH4Cl saturated solution 
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was added (10 mL) and the phase were separated. The aquous layer was further extracted 
with CH2Cl2 (5x 15 mL). The organic layers were dried on Na2SO4, filtered and 
concentrated. Purification of this residue by flash chromatography (5% MeOH in CH2Cl2 
eluent) furnished 3-hydroxyisoquinoline 63 (51 mg, 0.22 mmol). Overall, 3-
hydroxyisoquinoline 63 (375 mg, 1.54 mmol, 56% yield) was obtained as a yellow solid: 
Rf = 0.10 (95:5 CH2Cl2:MeOH) ; 1H NMR (500 MHz, CDCl3) δ 7.17 (s, 1H), 6.94 (s, 
1H), 6.52 (s, 1H), 3.91 (s, 3H), 3.82 (s, 3H), 3.01 (s, 3H), 2.29 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 161.99, 149.63, 149.62, 146.04, 142.71, 140.48, 121.54, 113.27, 104.86, 
60.63, 60.35, 21.23, 17.43; IR (NaCl/film) 2938, 1690, 1458, 1324 cm–1; HRMS (MM: 
ESI-APCI) m/z calc’d for C13H16O3N [M+H]+: 234.1125, found 234.1125. 
 
 
Isoquinoline triflate 58 
3-Hydroxyisoquinoline 163 was dissolved in dry CH2Cl2 (6 mL).  To this 
solution, was added pyridine (1.00 mL, 12.2 mmol), and the reaction was cooled to 0 °C.  
Triflic anhydride (0.31 mL, 1.83 mmol) was added dropwise to the cold solution, which 
was maintained at 0 °C for 40 minutes.  At this time, TLC analysis indicated complete 
consumption of the starting material.  The reaction was quenched at 0 °C by the addition 
of saturated aqueous NaHCO3 (10 mL) followed by warming to 23 °C.  The mixture was 
extracted with CH2Cl2 (3 x 30 mL), and the combined organic extracts were dried over 
Na2SO4 and concentrated under vaccuum.  The resulting residue was purified by flash 
chromatography (5% ethyl acetate in hexanes eluent) to furnish isoquinoline triflate 58 
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(433 mg, 97% yield):  Rf = 0.83 (hexanes:ethyl acetate 1:1); 1H NMR (500 MHz, CDCl3) 
δ 7.37 (s, 1H), 7.19 (s, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.05 (s, 3H), 2.42 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ158.84, 151.22, 150.68, 150.09, 139.41, 137.00, 123.79, 
123.11, 118.97 (q, J = 320 Hz), 107.83, 60.99, 60.38, 26.91, 17.20; IR (NaCl/film) 2961, 
2924, 2853, 1604, 1552, 1452, 1413, 1377, 1352, 1332, 1260, 1208, 1094, 1059, 1016, 
966, 940, 799, 699 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H10O2N [M+H]+: 
366.0618, found 366.0637. 
 
 
2-(Formamido)acrylic acid methyl ester 6017 
A mixture of serine methyl ester hydrochloric salt A2-10 (15.6 g, 100 mmol), 
K2CO3 (55.3 g, 400 mmol), and a catalytic amount of Et3N (160 µL) in methyl formate 
(320 mL) was stirred for 16 h at 23 °C. The salts were filtered, and the solvent was 
removed under reduced pressure. Quick purification by column chromatography 
(hexanes-ethyl acetate 40:60) afforded the desired product 60 (7.15 g, 55%). White solid, 
Rf 0.56 (hexanes:ethyl acetate 1:1), trans:cis 88:12. 1H NMR (300 MHz, CDCl3) δ 8.55 
(d, J = 11.2 Hz, 1H, cis), 8.39 (s, 1H, trans), 7.79 (br, 1H, trans), 7.52 (br, 1H, cis), 6.62 
(s, 1H, trans), 5.95 (s, 1H, trans), 5.67 (s, 1H, cis), 5.42 (s, 1H, cis), 3.84 (s, 3H). 13C 
NMR (125 MHz, CDCl3) δ 164.34, 161.14 (cis), 159.65 (trans), 130.35, 110.58 (trans), 
104.80 (cis), 53.25.  
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Isoquinoline 57,18 
 To silyl aryl triflate 59 (37 mg, 0.10 mmol) and methyl-2-formamidoacrylate (60, 
39 mg, 0.30 mmol) stirring in MeCN (10 mL) at 23 °C was added CsF (92 mg, 0.60 
mmol).  The flask was maintained at 23 °C for 6 hours.  Afterward, HCl 1N (1 mL) was 
added and the reaction was further stirred for 15 min. The mixture was then basified with 
NaHCO3 saturated solution and EtOAc was added. The phases were separated, and the 
aqueous layer was extracted with EtOAc (3x 20 mL). The organic layers were dried on 
Na2SO4, filtered and concentrated. The resulting red residue was purified by flash 
chromatography (25% ethyl acetate in hexanes eluent) to furnish isoquinoline 61 (10 mg, 
36% yield) as a red solid: Rf = 0.35 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, 
CDCl3) δ 9.48 (s, 1H), 8.42 (s, 1H), 7.49 (s, 1H), 4.04 (s, 3H), 4.03 (s, 3H), 3.99 (s, 3H), 
2.45 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.72, 151.15, 147.65, 147.35, 141.05, 
139.42, 132.91, 125.02, 124.29, 123.24, 61.80, 60.69, 53.01, 17.56; IR (NaCl/Film) 2949, 
2855, 1738, 1717, 1620, 1570, 1483, 1456, 1418, 1386, 1321, 1285, 1257, 1196, 1141, 
1105, 1085, 1006, 984, 906, 818, 802, 777 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for 
C11H10O2N [M+H]+: 262.1074, found 262.1070. 
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Isoquinoline N-oxide 57 
 To a solution of isoquinoline 61 (575 mg, 2.20 mmol) in dichloromethane (22 
mL) at 0 °C was added mCPBA (1.10 g, 4.40 mmol, 70% w/w). The reaction was 
allowed to reach 23 °C and was further stirred for 24 hours.  After this time, TLC 
analysis indicated complete consumption of the isoquinoline. The reaction mixture was 
directly purified by flash chromatography (10% acetone in dichloromethane to 10% 
acetone/ 2% MeOH in dichloromethane eluent) providing isoquinoline N-oxide 57 (421 
mg, 69% yield):  Rf = 0.12 (1:1 hexanes:ethyl acetate); 1H NMR (500 MHz, CDCl3) 
δ 8.95 (s, 1H), 7.86 (s, 1H), 7.33 (s, 1H), 4.01 (s, 3H), 3.96 (s, 3H), 3.95 (s, 3H), 2.38 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 162.65, 152.03, 144.45, 137.97, 137.41, 133.29, 
125.77, 125.17, 125.13, 123.72, 61.53, 60.66, 53.52, 17.14. IR (NaCl/film) 2951, 2850, 
1742, 1623, 1607, 1558, 1475, 1447, 1418, 1374, 1277, 1258, 1209, 1144, 1100, 1073, 
1002, 958, 936, 828 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C11H10O2N [M+H]+: 
278.1028, found 278.1034. 
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Bis-isoquinoline 64 
 Palladium acetate (34 mg, 0.15 mmol) was added to a flame-dried high pressure 
glassware containing cesium carbonate (280 mg, 0.86 mmol), cesium pivalate (136 mg, 
0.58 mmol) and di-tert-butylmethylphosphonium tetrafluoroborate (72 mg, 0.29 mmol).  
The vessel was sealed. The vessel evacuated and backfilled with nitrogen atmosphere 
three times.  Next, toluene (5 mL) was added to the reaction vial, which was subsequently 
heated to 60 °C in an oil bath.  The suspension was maintained at this temperature for 1 
hour with vigorous stirring.  Concomitant to this step, isoquinoline triflate 95 (106 mg, 
0.29 mmol) was added to a flask containing isoquinoline N-oxide 94 (240 mg, 0.86 
mmol). Toluene (10 mL) was added to the flask under an argon atmosphere. Upon 
cooling  the palladium solution to room temperature, the isoquinolines solution was 
added.  Next, the sealed tube was heated at 180 °C for 4 hours.  At the completion of this 
step, the content was filtered over a short plug of celite, the plug was washed with CH2Cl2 
and acetone. Removal of the solvent and purification of the crude residue by flash 
chromatography (25% ethyl acetate in hexanes to 50% ethyl acetate in hexanes to 10% 
acetone/ 2% MeOH in dichloromethane) yielded bis-isoquinoline 64 (87 mg, 63% yield) 
as a white solid, along with isoquinoline 61 (56 mg, 25% yield recovered) and 
isoquinoline N-oxide 57 (70 mg, 30% yield recovered). Bis-isoquinoline : Rf = 0.16 (1:1 
EtOAc:Hexanes) ; 1H NMR (500 MHz, CDCl3) δ 8.46 (s, 1H), 7.59 (s, 1H), 7.57 (s, 1H), 
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7.38 (s, 1H), 3.99 (s, 3H), 3.97 (s, 3H), 3.96 (s, 3H), 3.79 (s, 3H), 3.37 (s, 3H), 3.11 (s, 
3H), 2.45 (s, 3H), 2.43 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.82, 157.67, 155.46, 
152.70, 152.52, 150.55, 149.71, 149.08, 139.81, 138.99, 137.18, 135.16, 134.85, 124.78, 
124.21, 123.84, 123.52, 122.02, 117.04, 61.03, 60.72, 60.44, 60.24, 53.00, 27.04, 17.30, 
17.20; IR (NaCl/film) 2930, 1719, 1555, 1395, 1318, 1262, 1121, 1096 cm–1; HRMS 
(MM: ESI-APCI) m/z calc’d for C27H29O6N2 [M+H]+: 477.2020, found 477.2030. 
 
 
Isoquinoline 67  
TBAT (1.450 g, 2.686 mmol) was added to a flame-dried round bottom flask 
equipped with a magnetic stir bar.  The flask was sealed with a septum, evacuated and 
back-filled with N2. THF (6.0 mL) and methyl 2-acetamidoacrylate 65 (576.6 mg, 4.027 
mmol) were sequentially added via syringe.  To the solution was then added a solution of 
aryne precursor 59 (500.0 g, 1.343 mmol) in THF (7.0 mL), and the reaction mixture was 
stirred at room temperature for 20 hours.  The mixture was evaporated in vaccuo and the 
resulting residue was purified by silica gel flash column chromatography (0% ethyl 
acetate in hexanes to 50% ethyl acetate in hexanes) to give a mixture of isoquinoline 66 
and methyl 2-acetamidoacrylate (65) as a brown solid. 
The mixture was dissolved with THF (9.0 mL) and methanol (9.0 mL).  To the 
solution was added 2 M aqueous sodium hydroxide solution (9.06 mL, 18.12 mmol), and 
the reaction mixture was warmed up to 50 °C and stirred at 50 °C for one hour.  The 
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reaction mixture was allowed to cool to room temperature and acidified with 10% citric 
acid in water.  The mixture was extracted with dichloromethane/2-propanol (10:1, v/v).  
The combined organic layers were dried over anhydrous sodium sulfate, filtered and 
concentrated under reduced pressure to give a crude isoquinoline the carboxylic acid as a 
brown solid. 
The crude carboxylic acid, DL-serine methyl ester hydrochloride (355.2 mg, 
2.283 mmol), 1-hydroxybenzotriazole (HOBt) hydrate (235.9 mg, 1.746 mmol), 
triethylamine (0.49 mL, 3.49 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI) hydrochloride (437.7 mg, 2.283 mmol) and N,N-dimethylformamide (DMF, 4.0 
mL) were stirred at room temperature for 13 hours. Saturated aqueous sodium 
bicarbonate solution (20 mL) and water (10 mL) were added to the reaction mixture. The 
mixture was then extracted with ethyl acetate (2 x 30 mL, 1 x 20 mL).  The organic layers 
were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and 
evaporated under reduced pressure.  The resulting residue was purified by silica gel flash 
column chromatography (50% ethyl acetate in hexanes) to give 67 (174.3 mg, 0.4810 
mmol, 36% yield from 59) as a tan foam: Rf = 0.23 (50% ethyl acetate in hexanes); 1H 
NMR (500 MHz, CDCl3) δ 9.12 (d, J = 7.5 Hz, 1H), 8.24 (s, 1H), 7.49 (d, J = 1.2 Hz, 
1H), 4.94 (dt, J = 7.7, 4.0 Hz, 1H), 4.16 (t, J = 3.9 Hz, 2H), 4.00 (s, 3H), 3.99 (s, 3H), 
3.87 (s, 3H), 3.29 (s, 1H), 3.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.02, 165.30, 
156.09, 151.70, 149.48, 140.25, 137.64, 134.02, 125.05, 123.51, 118.36, 77.46, 77.21, 
76.95, 63.10, 60.61, 60.01, 55.03, 52.59, 26.95, 16.77 cm–1; HRMS (MM: ESI-APCI) m/z 
calc’d for C18H22N2O6 [M+H]+: 363.1551, found 363.1551.  
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Acrylate 68 
To a solution of methyl isoquinoline 67 (542.5 mg, 1.497 mmol) in 
dichloromethane (18.7 mL) were added EDCI hydrochloride (717.4 mg, 3.743 mmol) 
and copper (I) chloride (44.5 mg, 0.449 mmol).  The reaction mixture was stirred at room 
temperature for 5 hours. To the reaction mixture were then added saturated aqueous 
sodium bicarbonate (25 mL) and water (40 mL), and the mixture was extracted with 
dichloromethane.  The organic layers were combined, dried over anhydrous sodium 
sulfate, filtered and evaporated in vaccuo.  The resulting residue was purified by silica gel 
flash column chromatography (dichloromethane as eluent) to give 68 (457.1 mg, 1.327 
mmol 89% yield) as a white solid: Rf = 0.82 (50% ethyl acetate in hexanes); mp 155.0 ‒ 
156.0 °C (from dichloromethane and hexanes); 1H NMR (500 MHz, cdcl3) δ 10.79 (s, 
1H), 8.32 (m, 1H), 7.56 (dd, J = 0.9, 0.5 Hz, 1H), 6.89 (s, 1H), 6.06 (d, J = 1.6 Hz, 1H), 
4.03 (s, 3H), 4.00 (s, 3H), 3.97 (s, 3H), 3.20 (s, 3H), 2.51 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 164.60, 163.87, 156.31, 152.03, 149.81, 140.83, 138.03, 134.43, 131.37, 
125.23, 123.89, 118.47, 108.73, 77.28, 77.02, 76.77, 60.77, 60.15, 52.89, 27.32, 16.89 
cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C18H20N2O5 [M+H]+: 345.1445, found 
345.1430.  
 
N
OMe
MeO
Me
Me
N
H
O
CO2Me
OH
67
N
OMe
MeO
Me
Me
N
H
O
CO2Me
CuCl, EDCI•HCl
CH2Cl2, 23 °C
(89% yield)
68
Chapter 2 – Progress Toward the Total Synthesis of Jorumycin 65 
 
Bis-isoquinoline 64  
TBAT (8.114 g, 15.03 mmol) was added to a flame-dried round bottom flask 
equipped with a magnetic stir bar.  The flask was sealed with a septum, evacuated and 
back-filled with N2. THF (8.0 mL) and a solution of acrylate 26 (862.8 mg, 2.505 mmol) 
in THF (8.0 mL) were sequentially added via syringe.  A solution of aryne precursor 7b 
(2.799 g, 7.515 mmol) in THF (8.0 mL) was then added to the reaction mixture, which 
was stirred at room temperature for 20 hours.  The volatiles of the reaction mixture were 
removed in vaccuo, and the resulting residue was purified by silica gel flash column 
chromatography (0% ethyl acetate in hexanes to 70% ethyl acetate in hexanes) to give 22 
(494.9 mg, 1.038 mmol 42% yield) spectroscopic data can be found above. 
 
 
Bis-isoquinoline alcohol 56 
 Selenium dioxide (17 mg, 0.150 mmol) was added to a solution of 93 (35 mg, 
0.075 mmol) in dioxane (1.5 mL). The reaction mixture was subsequently heated to 110 
°C for 4 hours.  After this time, the solution was filtered on celite and washed with 
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EtOAc. The solvent was removed, and MeOH (4 mL) was added.  NaBH4 (17 mg, 0.45 
mmol) was subsequently added and the reaction was stirred for 12 h. At which time 
another portion of NaBH4 (17 mg, 0.45 mmol) was added, and the reaction was kept at 23 
°C for another 4 h.  After this period of time, water and EtOAc were added and the 
organic phases were separated.  Extraction of the aqueous layer with EtOAc, followed by 
drying the organic layers with Na2SO4, filtration and concentration gave the crude residue 
which was purified by flash chromatography (50% ethyl acetate in hexanes) yielded bis-
isoquinoline 56 (32 mg, 86% yield) as a off-white solid: Rf = 0.46 (60:40 
EtOAc:Hexanes) ; 1H NMR (500 MHz, CDCl3) δ 8.49 (s, 1H), 7.77 (s, 1H), 7.60 (s, 1H), 
7.46 (s, 1H), 5.28 (d, J = 2.6 Hz, 2H), 4.01 (s, 3H), 3.99 (s, 3H), 3.94 (s, 3H), 3.81 (s, 
3H), 3.32 (s, 3H), 2.47 (s, 3H), 2.45 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.65, 
156.97, 155.30, 152.62, 151.17, 150.44, 149.21, 148.86, 139.67, 139.23, 138.05, 135.08, 
134.64, 124.76, 124.22, 123.75, 123.62, 119.92, 117.86, 64.30, 60.98, 60.78, 60.42, 
60.33, 53.03, 17.31, 17.19; IR (NaCl/film) 3350, 2947, 2853, 1722, 1557, 1454, 1394, 
1323, 1263, 1121, 1098, 1009 cm–1; HRMS (MM: ESI-APCI) m/z calc’d for C27H29O7N2 
[M+H]+: 493.1969, found 493.1994. 
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Bis-terahydroisoqinoline 73 
 To bis-isoquinoline 56 (18 mg, 0.036 mmol) in acetic acid (1.5 mL) was added 
PtO2 (4 mg, 0.016 mmol).  The reaction mixture was putted under a hydrogen atmosphere 
and stirred at 23 °C for 24 h.  Upon complete conversion of the bis-isoquinoline by LC-
MS, the mixture was treated with NaOH 1N and dilute with dichloromethane.  The 
aqueous layer was further extracted with dichloromethane (4x), the organic phase dried 
on Na2SO4, filtered, concentrated.  The crude residue was then diluted in THF (1.5 mL) 
and H2O (1.5 mL), and lithium hydroxide was added (15 mg, 0.640 mmol). The reaction 
mixture was stirred at 23 °C for 20 h and was followed by LC-MS.  Upon completion, the 
reaction mixture was diluted with water and dichloromethane. The phases were 
separated, and the aqueous layer was further extracted with dichloromethane (4x), the 
organic phases dried on Na2SO4, filtered, concentrated.  The residue was then diluted in 
MeCN (2 mL) and formaldehyde (0.15 mL, 37% w/w) was added.  The mixture was 
stirred for 15 minute at 23 °C.  Afterward, NaBH3CN (20 mg, 0.320 mmol) was added 
and the reaction kept at 23°C for 30 min.  HCl 2N (2 mL) was added and the solution 
stirred for 24 h.  The mixture was then poured in NaHCO3 saturated solution, 
dichloromethane was added and the phases separated.  The aqueous phase was washed 4x 
with dichloromethane, and the organic phases were dried on Na2SO4, filtered and 
concentrated.  The residue was purified by prep TLC (4% MeOH/1% Et3N/ 95% 
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CH2Cl2), affording the bis-tetrahydroisoquinoline intermediate 73 (4 mg, 21% yield); 1H 
NMR (500 MHz, CDCl3) δ 6.73 (s, 1H), 6.70 (s, 1H), 5.74 (dd, J = 6.2, 3.8 Hz, 1H), 4.14 
(dd, J = 3.8, 1.3 Hz, 1H), 3.99 (dt, J = 12.7, 2.9 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.74 
(s, 6H), 3.68 (dt, J = 6.8, 1.2 Hz, 1H), 3.43 (dt, J = 9.9, 4.5 Hz, 1H), 3.26-3.17 (m, 2H), 
3.05 (s, 1H), 2.93 (dd, J = 15.2, 2.5 Hz, 1H), 2.87 (d, J = 17.2 Hz, 1H), 2.45 (s, 3H), 2.26 
(dd, J = 15.2, 12.7 Hz, 1H), 2.21 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 173.43, 150.89, 
149.90, 149.64, 149.41, 132.22, 132.12, 131.66, 128.87, 126.20, 125.04, 124.73, 122.28, 
69.22, 60.73, 60.51, 60.26, 60.17, 60.09, 59.10, 55.82, 53.00, 40.36, 31.88, 28.99, 16.03, 
15.93. 
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Figure A2.1.2 Infrared spectrum (thin film/NaCl) of compound 61 
Figure A2.1.3 13C NMR (125 MHz, CDCl3) of compound 61 
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Figure A2.2.3 13C NMR (125 MHz, CDCl3) of compound 75 
Figure A2.2.2 Infrared spectrum (thin film/NaCl) of compound 75 
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 Figure A2.3.2 13C NMR (126 MHz, CDCl3) of compound 63. 
 
Figure A2.3.2 Infrared spectrum (Thin Film, NaCl) of compound 63. 
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Figure A2.4.3. 13C NMR (125 MHz, CDCl3) of compound 58. 
Figure A2.4.2. Infrared spectrum (thin film/NaCl) of compound 58. 
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 Figure A2.5.3. 13C NMR (126 MHz, CDCl3) of compound 64. 
 
Figure A2.5.2. Infrared spectrum (Thin Film, NaCl) of compound 64. 
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 Figure 2.6.3. 13C NMR (126 MHz, CDCl3) of compound 67. 
 
Figure 2.6.2. Infrared spectrum (Thin Film, NaCl) of compound 67. 
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 Figure A2.7.3. 13C NMR (126 MHz, CDCl3) of compound 68. 
 
Figure A2.7.2. Infrared spectrum (Thin Film, NaCl) of compound 68. 
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 Figure A2.8.3. 13C NMR (126 MHz, CDCl3) of compound 56. 
 
Figure A2.8.2. Infrared spectrum (Thin Film, NaCl) of compound 56. 
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 Figure A2.9.3. 13C NMR (126 MHz, CDCl3) of compound 73. 
 
Figure A2.9.2. Infrared spectrum (Thin Film, NaCl) of compound 73. 
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Appendix 3 
A Tin-Free Route to a Complex Aryne Precursor 
 
A3.1 Introduction and Synthesis 
 The synthetic sequence originally devised for the preparation of aryne precursor 
59 proved to be reliable and high yielding.1  However the third step of the route relied on 
the cross-coupling of 3-bromovanillin (A2-1) with tetramethyl tin (Scheme A3-1).  While 
this reaction proceeded in quantitative yield, its sensitivity to oxygen and its use of a 
highly toxic stannane (i.e. tetramethyl tin) limited its scalability.  To overcome this 
challenge, we developed a tin-free route to benzaldehyde A2-4. 
 
Scheme A3-1. First generation synthesis of benzaldehyde A2-4. 
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 We began with the Wolff–Kishner reduction of ortho-vanillin (A3-1), which upon 
treatment with hydrazine monohydrate and potassium hydroxide afforded 6-methyl 
guaiacol (A3-2) in quantitative yield (Scheme A3-2).  This synthetic step could be 
performed on 100 g (657.2 mol) scale.  With 6-methyl guaiacol (A3-2) in hand, we 
sought to prepare aldehyde A3-4 using a Duff reaction.  Exposure of 6-methyl guaiacol 
(A3-2) to hexamethylenetetramine (HMTA) (3-3) in acetic acid furnished benzaldehyde 
A3-4 in 62% yield in a regioselective manner.  The Duff reaction to prepare this aldehyde 
could be carried out on as large as 180 g scale with without loss of yield.  Methylation of 
phenol A3-4 using MeI could be accomplished in 85% yield give aldehyde A2-4.  This 
synthetic sequence allows us to access the identical benzaldehyde intermediate (A2-4) 
used in our first generation synthesis, however in a more scalable fashion, providing 125 
g of the desired arene (A2-4).  This material was taken forward as previously disclosed to 
afford aryne precursor 59 in just 4 steps and 76% yield from aldehyde A2-4.  
 
Scheme A3-2. Preparation of Benzaldehyde A2-4. 
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A3.2 Experimental Section 
A3.2.1  Materials and Methods 
Unless stated otherwise, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents (distilled or passed 
over a column of activated alumina).  Commercially obtained reagents were used as 
received.  Reaction temperatures were controlled by an IKAmag temperature modulator.  
Thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 F254 
precoated plates (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, or CAM staining.  SiliaFlash P60 Academic Silica gel (particle size 
0.040-0.063 mm) was used for flash chromatography.  1H and 13C NMR spectra were 
recorded on a Varian 500 (at 500 MHz and 125 MHz, respectively) and are reported 
relative to CHCl3 (δ 7.24).  Data for 1H NMR spectra are reported as follows: chemical 
shift (δ ppm) (multiplicity, coupling constant (Hz), integration).  Data for 13C spectra are 
reported in terms of chemical shift relative to CHCl3 (δ 77.23).  IR spectra were recorded 
on a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of 
absorption (cm–1). HRMS were acquired using an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric 
pressure chemical ionization (APCI) or mixed (MM) ionization mode. 
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A3.2.2 Experimental Procedures 
 
6-methyl guaiacol (A3-1) 
O-vanillin (A3-1) (100.0 g, 0.6572 mol) was dissolved in triethylene glycol (500.0 mL) 
in a 3-neck round-bottom flask equipped with a reflux condenser, overhead stirrer and an 
internal thermometer.  Hydrazine monohydrate was added (63.5 ml, 1.31 mol) dropwise 
through the condenser. The reaction mixture was heated to 110 °C for 10 min.  After 
which time, the reaction was cooled to ~90 °C and KOH (228.0 g, 4.063 mol) was added 
portion-wise. (WARNING: Addition of KOH was exothermic and gas evolved). The 
orange solution was heated to 150 °C for 12 h. The reaction was then cooled to room 
temperature and the base neutralized (pH = 7) using NH4Cl (aq.). This was extracted 4 
times with CHCl3. The organic layers were combined, washed with brine, dried over 
Na2SO4, filtered and volatiles were removed in vacuo to afford 6-methyl guaiacol (A3-2, 
90.81g, 0.6572 mol, 99% yield). Spectroscopic data were identical to literature reported 
values.2  
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Benzaldehyde A3-43 
6-methyl guaiacol (A3-2) (181.6 g, 1.314 mol) was placed in a 12 L 3-neck round-bottom 
flask equipped with an overhead stirrer, temperature probe and reflux condenser to this 
flask was added acetic acid (6.0 L).  Hexamethylenetetramine (460.5 g. 3.285 mol) was 
added portion-wise. A small increase in temperature was observed during addition (~8 
°C).  The reaction mixture was stirred and heated to an internal temperature of 100 °C 
using a heating mantle. It was kept at 100 °C for 96 h.  The yellow/orange solution 
darkened to brown over the course of the reaction.  At this time the heating mantle was 
removed and volatiles were removed in vacuo. The brown residue was split into two parts 
for ease of handling. Water was added to each part and extracted with CH2Cl2 (4 x 200 
mL). The organic layers were combined and washed with brine. The organic layers were 
then dried over Na2SO4, filtered and the volatiles were removed in vacuo. The residue 
was filtered through a silica pad using 50% EtOAc in Hexanes. The solvent was removed 
in vacuo. The desired aldehyde (A3-4) could be recrystallized from CH2Cl2 (136.0 g, 
0.8180 mol, 61% yield) as a tan solid. Rf = 0.36 (20% EtOAc in Hexanes); 1H NMR; 
(500 MHz, CDCl3) δ 9.80 (s, 1H), 7.31 (m, 1H), 7.29 (m, 1H), 6.28 (s, 1H), 3.96 (s, 3H), 
2.32 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.17, 149.74, 146.70, 128.88, 128.80, 
124.03, 106.68, 77.27, 77.02, 76.76, 56.21, 15.28; IR (NaCl/film) 3322, 3007, 2841, 
1665, 1651, 1593, 1501, 1463, 1428, 1404, 1366, 1311, 1195, 1146, 1094, 1011, 985, 
Me
HO
OMe
(HMTA) 
A3-3
AcOH
100 °C, 96 h
62% yield
N
N
N
N
A3-2
Me
HO
OMe
A3-4
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931, cm–1; HRMS (MM: ESI-APCI) m/z  calc’d for C9H10O3 [M+H]: 167.0703, found 
167.0709. 
 
 
Benzaldehyde A2-4 
Phenol A3-4 (1.00 g, 6.02 mmol) and K2CO3 (1.22 g, 9.02 mmol) were dissolved in dry 
DMF (9.0 mL)4 in a flame-dried round bottom flask equipped with a magnetic stir bar 
and a rubber septum under nitrogen atmosphere.  Methyl iodide (0.450 mL, 7.22 mmol) 
was added drop-wise via syringe and the reaction was stirred at ambient temperature for 
24 h. At which time, 20 mL of saturated aqueous NaHCO3 was added. This was then 
extracted with Et2O (3 x 25 mL).  The organic layers were combined, washed with water 
(2 x 25 mL), dried over Na2SO4, filtered and the volatiles were removed in vacuo to 
cleanly afford desired benzaldehyde A2-4 (0.918 g, 5.09 mmol, 85% yield) without need 
for further purification.  Spectroscopic data were identical to that reported in chapter 1 of 
this thesis.  
  
MeI, K2CO3
DMF, 23 °C 24 h
(85% yield)
Me
MeO
OMe
CHOMe
HO
OMe
CHO
A3-4 A2-4
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Figure A3.1.3 13C NMR (126 MHz, CDCl3) of compound A3-4. 
 
Figure A3.1.2 Infrared spectrum (Thin Film, NaCl) of compound A3-4. 
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Scheme A4-1. Preparation of aryne precursor 59. 
 
 
Scheme A4-2. Aryne annulations  
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Scheme A4-3. Cross-coupling of isoquinolines 57 and 58.   
 
 
Scheme A4-4. Alternative approach to bis-isoquinoline XX.  
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Scheme A4-5. Origins of Diastereoselectivity for the Reduction of Bis-Isoquinoline XX. 
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Scheme A4-6. Completion of the Synthesis of Jorumycin. 
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CHAPTER 3 
Decarboxylative Cross-Coupling of (2-azaaryl)carboxylates with Aryl 
Halides 
 
3.1 Introduction 
The 2-substituted pyridine motif (Figure 3.1), is present in a number of important 
small molecules, 1  however 2-azaaryl nucleophiles typically used in cross-coupling 
reactions, such as organozincs, Grignards, organolithiums, organostannanes, and boronic 
acids, are notoriously unstable and difficult to prepare.2  While some modifications have 
been made to improve their synthetic viability, especially within the realm of boronic 
acid derivatives, these approaches are often inconvenient or produce toxic waste.3  The 
development of a decarboxylative method of generating these organometallic species 
(e.g., 86) in situ from (2-azaaryl)carboxylates (85) represents a desirable alternative to 
traditional aryl nucleophiles for the synthesis of 2-aryl pyridine structures (87) (Scheme 
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3.1).  2-(azaaryl)carboxylates are generally inexpensive, are stable to both air and water, 
and represent a more ecologically friendly alternative to their organometallic 
counterparts.  
Figure 1.1. The importance of 2-substituted pyridine. 
 
 
Scheme 3.1. Decarboxylative cross-coupling of aryl carboxylic acids with aryl halides. 
 
Myers and co-workers reported the first practical decarboxylative cross-coupling 
in 2002,4 a palladium-catalyzed decarboxylative Heck-type olefination (Scheme 3.2).  
This work demonstrated that olefinated arenes are accessible from benzoic acids and 
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olefins in the presence of catalytic palladium(II) triflate and silver carbonate.  This 
represented an important advance as it provided an alternative to aryl halides and aryl 
pseudo-halides usually used in Heck reactions.  A critical development within the field of 
decarboxylative cross-coupling was reported in 2006; Goossen and co-workers disclosed 
a catalytic decarboxylative cross-coupling reaction, utilizing a dual-catalyst system of 
copper and palladium.  Mechanistically, this dual catalyst approach likely proceeds 
through a decarboxylative cupration of the arylcarboxylate partner.  The resulting aryl 
copper species subsequently undergoes transmetallation onto the palladium, which 
furnishes the coupled product through reductive elimination (Figure 3.2).5  Unlike typical 
cross-couplings, which require stoichiometric aryl organometallic nucleophiles, 
decarboxylative couplings proceed through an in situ generation of the nucleophilic 
coupling partner.  
A variety of non-aryl carboxylates have proven to act as efficient coupling 
partners in decarboxylative cross-coupling reactions,6 including alkynes,7 α-keto acids,8 
and 2-(2-azaaryl)acetates.9  While these represent great advances within the field, the 
robust coupling of a key class of molecules, namely 2-(azaaryl)carboxylates, has been 
elusive.  Recently, during the course of our own work on this topic, Wu and co-workers 
reported on the palladium-catalyzed decarboxylative cross-coupling reactions of 2-
picolinic acid.10  In light this work, we sought to supplement their studies with our own 
findings. 
Our laboratory became interested in the cross-coupling to (2-azaaryl)nucleophiles 
within the context of jorumycin. We sought to prepare the bisisoquinoline 100 via a 
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convergent cross-coupling between two aryl fragments. Because both of our coupling 
partners were isoquinolines, we initiated exploration of the decarboxylative cross-
coupling between 3-triflyl isoquinoline 98 and 1-carboxy isoquinoline 99 (Scheme 3.3).  
Owing to the importance of these motifs, we also looked to develop a general method of 
performing the decarboxylative cross-coupling of (2-azaaryl)carboxylates with aryl 
electrophiles. 
 
Scheme 3.2. Myers’s decarboxylative olefination and Goossen’s decarboxylative coupling of benzoic 
acids and aryl bromides. 
 
Both of the isoquinoline fragments necessary for the decarboxylative cross-
coupling could be prepared utilizing methodologies developed within our laboratory 
which exploit the unique reactivity of arynes.  Isoquinoline triflate 99 could be accessed 
through the acyl-alkylation of aryne-precursor 59 followed by condensation with 
ammonium hydroxide to afford 3-hydroxy isoquinoline 63, which could be quantitatively 
triflated using triflic anhydride to furnish our electrophilic coupling partner (98).  
R1
R2
CO2H
R2 = OMe, NO2, F, Cl, Me
93
Pd(O2CCF3)2, Ag2CO3
5% DMSO-DMF
80 – 120 ºC
R3
R2
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95
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R2 = NO2, CHO, OMe
NHC(O)CH3, SO2CH3
93
R2
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R1
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CuI (0.05 equic), Pd(acac)2 (0.03 equiv), 1,10 Phen.
K2CO2, 3Å MS, NMP, 160 ºC, 24 h
CuCO3 (1.5 equiv), Pd(acac)2 (0.01 equiv), P(i-Pr)Ph2
KF, 3Å MS, NMP, 120 ºC, 24 h
+
Br
R3
R3
96
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Scheme 3.3. The decarboxylative cross-coupling of two isoquinolines for the total synthesis of 
jorumycin. 
 
1-carboxy isoquionoline 99 was prepared using our aryne annulation 
methodology, in which aryne precursor 59 is treated with a fluoride source and methyl 
acetamido acrylate 65. The methyl group could be selectively oxidized in a two-step 
protocol to the carboxylic acid (99).  Because each of these coupling partners requires 
many steps to prepare, we focused our efforts on developing a more general approach to 
this problem.  
 
Scheme 3.4. Preparation of isoquinoline triflate 98 and carboxylic acid 99.                       ```
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3.2 Optimization of a Decarboxylative Cross-coupling of Picolinic Acid with 
Bromobenzene  
To develop a general cross-coupling methodology, we selected simple substrates for 
optimization studies, namely picolinic acid (102) and bromobenzene (103, Table 3.1).  
We began our investigations by applying conditions similar to those reported by Goossen 
with disappointing results. (Table 3.1, entry 1).  Using the same catalyst system we 
examined microwave irradiation and observed an increase in yield over heating in an oil 
bath (Table 3.1, entry 2).  Similar results were disclosed by Goossen and Crabtree who 
independently reported enhanced yields using microwave irradiation.11 
With these initial results in hand we set about screening palladium and copper 
sources.  Both palladium(II) and palladium(0) sources were examined, with palladium(II) 
iodide providing 2-phenyl pyridine (104) in 36% yield (Table 3.1, entry 2). Ultimately, 
cuprous oxide (Cu2O), the copper source reported by Goossen and co-workers, gave 
consistently higher yields than copper (I) halides (Table 3.1, entries 12–16). Importantly, 
for both copper and palladium sources, weakly coordinating counterions were favored.  
While these results were encouraging, we sought to further improve the system.  
Concurrent with these studies, we examined several other solvents, however were limited 
to high boiling solvents as a consequence of the temperatures required for the copper-
catalyzed decarboxylation of picolinic acid (Table 3.1, entries 17–20).  
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Table 3.1. Decarboxylative cross-coupling of picolinic acid with aryl halides.  
 
 
With these copper and palladium sources, we next examined several phosphine 
ligands.  None showed improvement over the triphenylphosphine used in our initial 
studies.  During the course of our studies we discovered that preheating the mixture at 50 
ºC for 10 minutes prior to heating to 190 ºC was advantageous.  Gratifyingly, we 
discovered that changing from the bidentate ligand 1,10 phenanthroline to the 
monodentate ligand pyridine caused a substantial increase in yield (Table 3.2, entry 6). 
 
8 Cu2O Pd(acac)2 170 µwave 8
9 Cu2O Pd(TFA)2 170 µwave
10 Cu2O Pd(F6-acac)2 170 µwave
14
6
NMP
NMP
NMP
2 Cu2O PdI2 170 µwave
1 Cu2O PdI2 170 Oil bath
36
6
NMP
NMP
3 Cu2O PdI2 120 µwaveNMP
Entry Cu Source Pd Source Temperature(ºC)
Heat
Source % Yield*Solvent
-
4 Cu2O PdCl2 170 µwave
5 Cu2O PdBr2 170 µwave
7 Cu2O Pd(OAc)2 170 µwave
9
12
6
NMP
NMP
NMP
6 Cu2O PdI2 170 µwave 36NMP
13 CuCl PdI2 170 µwave
14 CuBr PdI2 170 µwave
15 CuI PdI2 170 µwave
7
16
31
16 CuOTf PdI2 170 µwave 20
NMP
NMP
NMP
NMP
17 Cu2O(1.0eq) PdI2 170 µwave 7NMP
11 Cu2O Pd(PPh3)4 170 µwave
12 Cu2O Pd2(dba)2 170 µwave
13
14
NMP
NMP
18 Cu2O PdI2 170 µwave
19 Cu2O PdI2 170 µwave
20 Cu2O PdI2 170 µwave
12
4
18
21 Cu2O PdI2 170 µwave 2
DMSO
NMP:Quin(1:1)
Toluene
DMF
Conditions: 0.4645 mmol 102, 1.3935 mmol 103, 10% mol Cu, 5% mol Pd, 15% mol PPh3, 30% mol 1,10 phen., 0.5 
mL Solvent *Yields determined by LCMS analysis with 4,4' di-tert-butyl biphenyl as internal standard
Cu source, Pd source
PPh3,1,10  phen.
Solvent, 3 h
N
O
OH Br N
102 103 104
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Table 3.2. Investigation of P- and N- ligands for the decarboxylative cross-coupling of picolinic acid 
with aryl halides. 
  
 
The implementation of a pre-formed potassium picolinate salt lead to a 10% increase in 
yield over its in situ generated counterpart (Table 3.2, entry 7).  In examining the 
stereoelectronics of the N-ligand we discovered sterically encumbered nitrogen-contain 
ligands proved detrimental to the yield (Table 3.2, entries 8 and 13), while both electron-
rich and deficient ligands also did not improve yields.  Interestingly, as observed with 
1,10 phenanthroline, other bidentate ligands such as TMEDA lead to lower yields (Table 
3.2, entry 15).  We hypothesize the formation of a stable 18 electron copper complex (12) 
is detrimental to decarboxylation (Figure 3.3). 
1 H Cu2O PdI2 dppm 1,10 Phen 170 µwave
2 H Cu2O PdI2 dppb 1,10 Phen 170 µwave
3 H Cu2O PdI2 dppe 1,10 Phen 170 µwave
K2CO3
7
16
K2CO3 31
4 H Cu2O PdI2 BINAP 1,10 Phen 170 µwave
5 H Cu2O PdI2 PPh3/KF 1,10 Phen 170 µwave K2CO3
6
2
K2CO3
K2CO3
NMP
NMP
NMP
NMP
NMP
Entry R Cu Source Pd Source PhosphineLigand
Nitrogen 
Ligand
Temperature
(ºC)
Heat
Source Base % Yield*Solvent
8 K Cu2O PdI2 PPh3 2,6 Lutidene 50→190 µwave
9 K Cu2O PdI2 PPh3 Ethyl Isonicotinate 50→190 µwave
- 46
- 49
NMP
NMP
10 K Cu2O PdI2 PPh3 DMAP 50→190 µwave - 56NMP
11 K Cu2O PdI2 PPh3 4-MeO Pyridine 50→190 µwave - 43NMP
12 K Cu2O PdI2 PPh3 DABCO 50→190 µwave
13 K Cu2O PdI2 PPh3 50→190 µwave
43
38
NMP
NMP Et3N
14 K Cu2O PdI2 PPh3 Hunig's Base 50→190 µwave
15 K Cu2O PdI2 PPh3 50→190 µwave
60
27
NMP
NMP TMEDA
16 K Cu2O PdI2 PPh3 50→190 µwave 51NMP (iPr)2NH
17 K Cu2O PdI2 PPh3 50→190 µwave 62NMP Quinuclidine
6 H Cu2O PdI2 PPh3 Pyridine 50→190 µwave
7 K Cu2O PdI2 PPh3 Pyridine 50→190 µwave
K2CO3 52
- 62
NMP
NMP
-
-
-
-
-
-
Conditions: 0.4645 mmol 105, 1.3935 mmol 103, 10% mol Cu, 5% mol Pd, 15% mol P-ligand, 30% mol N-ligand, 0.5 mL Solvent *Yields determined by 
LCMS analysis with 4,4' di-tert-butyl biphenyl as internal standard
Cu source, Pd source
P–Ligand, N–Ligand
Solvent, 3 h
N
O
OR Br N
105 103 104
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Scheme 3.5. Proposed mechanism of the decarboxylative cross-coupling of picolinic acid with aryl 
halides. 
 
With a suitable N-ligand in hand we hoped to gain better insight into the influence of the 
P-ligands on our catalytic system; like their nitrogen counter parts, bidentate phosphorous 
ligands performed poorly under the reaction conditions (Table 3.3, entries 8 and 13).  We 
also reexamined copper sources, this time including copper(II) salts (Table 3.3, entries 
16–20).  All of these were inferior to copper(I) oxide.  We investigated other counter ions 
of the picolinate salts such as cesium and sodium (Table 3.3, entries 14 and 15).  None of 
these fared as well as potassium; confirming a trend was also observed in Goossen’s 
studies.  
N[Cu]
N
O
O–[Cu]
[CuI] X-
N
O
OK
transmetallation
ion
exchange
CO2
PdL2
Br
PdL2
N N
reductive
elimination
Broxidative
addition
106
105
110 104
decarboxylation
103
109
107
N
Cu
O
O
N N
‡
proposed transition state
L2Pd0
51
108
Cu
N N
‡
proposed transition state
N O
O
112 113
Chapter 3 – Decarboxylative Cross-Coupling of (2-azaaryl)carboxylates with 
Aryl Halides 
 
 
114 
Table 3.3. Investigation of P-ligands and copper sources for the decarboxylative cross-coupling of 
picolinic acid with aryl halides.   
 
 
One of the unproductive side-reactions of our decarboxylative cross-coupling is the 
formation of biphenyl through an Ullmann-type dimerization of bromobenzene. By 
modulating the stoichiometry of bromobenzene (103) we attempted to suppress the 
unproductive dimerization and increase cross-coupling (Table 3.4).  Ultimately, reducing 
the equivalents of bromobenzene from 3.0 to 2.0 was slightly beneficial to our yield 
(Table 3.4, entry 5). 
  
1 K Cu2O P(o-Tolyl)3
2 K Cu2O P(Cy)3
26
42
3 K Cu2O P(t-Bu)3
4 K Cu2O P(2-Furyl)3
21
42
5 K Cu2O P((CF3)2Ph)3
6 K Cu2O P(4-MeO-Ph)3
36
45
7 K Cu2O P(EtO)3
8 K Cu2O dppe
31
46
9 Cu2O
10 Cu2O
49
20
Ph2PO
(PhO)2POH
K
K
11 Cu2O 44JohnPhosK
Entry R Cu Source P-Ligand % Yield*
12 K Cu2O AsPh3
13 K Cu2O BINAP
48
38
14 Cu2O
15 Cu2O
4
1
PPh3
PPh3
Na
Cs
17 K Cu2(CO3)(OH)2 PPh3
18 K Cu(SO4) PPh3
29
47
19 K CuO PPh3
20 K Cu(OTf)2 PPh3
27
31
16 K Cu(OAc) PPh3 34
Conditions: 0.4645 mmol 105, 1.3935 mmol 103, 10% mol Cu, 5% mol 
Pd, 15% mol P-ligand, 30% mol N-ligand, 0.5 mL NMP *Yields 
determined by LCMS analysis with 4,4' di-tert-butyl biphenyl as internal 
standard
Cu source, PdI2
P–Ligand, pyridine
NMP, 3 h
N
O
OR Br N
105 103 104
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Table 3.4. Examination of the equivalents of bromobenzene in the decarboxylative cross-coupling of 
picolinic acid with aryl halides. 
 
 
Concurrent to these studies, we examined the impact of reaction times on the yield of our 
cross-coupling.  Though a reaction time of 8 hours provided the highest yield of 2-
phenylpyridine at 72%, it represented only a marginal improvement over shorter times 
(Table 3.5).   
 
Table 3.5. Examination of reaction time in the decarboxylative cross-coupling of picolinic acid with 
aryl halides. 
 
 
1 3.0
2 2.0
62
65
3 1.0
4 0.75
55
57
Entry Bromobenzene (equiv) % Yield*
N
O
OK Br
Cu2O, PdI2, PPh3
Pyridine, NMP
 50→190 ºC, µwave, 3 h
N
105 103 104
Conditions: 0.4645 mmol 105, X mmol 103, 
10% mol Cu2O, 5% mol PdI2, 15% mol 
PPh3, 30% mol pyridine, 0.5 mL NMP 
**Yields determined by LCMS analysis with 
4,4' di-tert-butyl biphenyl as internal 
standard
1
2
15
38
3 64
Entry % Yield*
4
5
62
69
0.5
2.5
Time (h)
4
1.0
5
6 728
N
O
OK Br
Cu2O, PdI2, PPh3
Pyridine, NMP
 50→190 ºC, µwave, 3 h
N
105 103 104
Conditions: 0.4645 mmol 105, 0.929 mmol 
103, 10% mol Cu2O, 5% mol PdI2, 15% 
mol PPh3, 30% mol pyridine, 0.5 mL NMP 
**Yields determined by LCMS analysis with 
4,4' di-tert-butyl biphenyl as internal 
standard
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In order to better understand the reaction mechanism, we performed a series of control 
experiments in which we omitted each of the reagents.  We discovered pyridine was not 
able to facilitate the necessary deprotonation of picolinic acid in situ (Table 3.6, entry 1).  
Omission of triphenylphosphine substantially decreased the yield of 2-phenyl pyridine 
(10) (Table 3.6, entry 2). Both copper and palladium proved crucial for our reaction; 
removal of either metal lead to little or no reactivity (Table 3.6, entries 3 and 4).  
Ultimately, pyridine was not necessary to facilitate the reaction (Table 3.6, entry 5).  
However this is most likely due to an unproductive protodecarboxylative side reaction 
that produces pyridine from picolinic acid. 2-Phenylpyridine is a common substrate for 
functional group directed C–H activation and can serve as a ligand for copper or 
palladium.12 Consequently, we explored the possibility of product inhibition.  However, 
yields were not effected by addition of 2-phenylpyridine to the reaction (Table 3.6, entry 
6), ruling out this inhibitory interaction. 
 
Table 3.6. Control experiments for the decarboxylative cross-coupling of picolinic acid with aryl 
halides. 
 
1 H Cu2O PdI2 PPh3 pyridine 50→190 µwave
2 K Cu2O PdI2 - pyridine 50→190 µwave
Pyridine 5
- 22
NMP
NMP
3 K - PdI2 PPh3 pyridine 50→190 µwave - 9NMP
4 K Cu2O - PPh3 pyridine 50→190 µwave
5 K Cu2O PdI2 PPh3 - 50→190 µwave
- 0
- 62
NMP
NMP
Entry R Cu Source Pd Source PhosphineLigand
Nitrogen 
Ligand
Temperature
(ºC)
Heat
Source Addative % Yield*Solvent
Cu source, Pd source
P–Ligand, N–Ligand
Solvent, 3 h
N
O
OR Br N
105 103 104
Conditions: 0.4645 mmol 105, 0.929 mmol 103, 10% mol Cu2O, 5% mol PdI2, 15% mol PPh3, 30% mol pyridine, 0.5 mL NMP **Yields determined by LCMS 
analysis with 4,4' di-tert-butyl biphenyl as internal standard
6 K Cu2O PdI2 PPh3 pyridine 50→190 µwave 65NMP 2-phenylpyridine
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3.3 The cross-coupling of (2-azaaryl)carboxylates with aryl halides 
With our best conditions to date identified, we turned our attention to examination of the 
substrate scope of the decarboxylative cross-coupling (Figure 4).  Electronically neutral 
aryl halides (104 and 117) performed well under the reaction conditions. Both electron 
rich and electron deficient aryl halides fared modestly (118 and 119).  One of the major 
byproducts of reactions using electron deficient aryl bromides was an Ullmann-type 
coupled product.  Heteroaromatic halides produced coupled products in disappointingly 
low yields (123 and 124).  Most interestingly, other (2-azaaryl)carboxylates performed 
well under the reaction conditions (125 and 126). 
 
Table 3.7. The decarboxylative cross-coupling of picolinic acid with aryl halides.  
 
N
X
O
OK Br
Cu2O, PdI2, PPh3
Pyridine, NMP
 50→190 ºC, µwave, 6 h
R
N
X
R
N
Me
117
59% yield
N
104
72% yield
N
CN
118
20% yield
N
N
123
>5% yield
N
N
124
>5% yield
N
N
125
39% yield
N
N
OMe
119
22% yield
N
NO2120
11% yield
N
122
37% yield
N
121
12% yield
126
50% yield
Conditions: 0.4645 mmol 114, 0.929 mmol 115, 10% mol Cu2O, 5% mol PdI2, 15% mol PPh3, 30% mol pyridine, 0.5 mL NMP, *isolated yields
114 115 116
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 Lastly, attempts to perform the decarboxylative cross-coupling within the context 
of our synthesis of jorumycin proved unfruitful, resulting mainly in the proto-
decarboxylation of carboxy isoquinoline 99. 
3.4 Conclusion  
Decarboxylative coupling is an attractive alternative to traditional cross-coupling 
reactions.  The starting materials are stable and inexpensive, and the byproducts of these 
reactions are less toxic and easier to dispose of than traditional organometallic reagents 
and boronic acids.  2-metallated heteroarenes are particularly unstable, difficult to 
prepare and expensive.  Herein we have reported an approach to circumvent the need to 
use these undesirable reagents.  We have shown that 2-(azaaryl)carboxylates can be 
effectively used in decarboxylative cross-coupling reactions with aryl halides to furnish 
2-(azaaryl)arenes, a motif present in a wide variety of important small molecules.  
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3.5 EXPERIMENTAL SECTION 
Spectral data for compounds 104, 117, 118, 119, 120, 121, 122, 123, 124, 125 and 126 
were consistent with previously reported data.10,13, 14 
A representative procedure for the decarboxylative cross-coupling of (2-
azaaryl)carboxylates with aryl halides: 
2-phenylpyridine (104) The potassium salt of picolinic acid (105) (74.9 mg, 0.464 
mmol), PPh3 18.3 mg (0.0697 mmol) PPh3, 8.4 mg (0.046 mmol) PdI2, and 6.6 mg (0.046 
mmol) Cu2O were added to a flame-dried 2.0 mL microwave vial equipped with a spin 
vane. The vial was sealed, evacuated and back-filled with argon (3 times). 0.50 mL NMP 
(degassed with Ar, >10 min.) and 97.6 µL (0.929 mmol) bromobenzene (103) were added 
sequentially via syringe. The mixture was stirred at room temperature for 10 min. The 
mixture was then irradiated in the microwave, with a 90 s prestirring period followed by 
10 min at 50 °C and increase in temperature to 190 °C. The reaction was heated at this 
temperature for 6 h.  The crude mixture was purified on a silica column.         
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Appendix 5 
The Ring-Expansive Acyl-Alkylation of Arynes 
  
A5.1 Introduction 
The ring-expansive direct acyl alkylation of arynes has been successfully 
showcased in the total synthesis of a number of natural products to date by the Stoltz 
group, including (+)-amurensinine (A5-5) and (–)-curularin (A5-10). 1 , 2  The 2006 
synthesis of (+)-amurensinine began with the acyl-alkylation of an aryne generated in situ 
from sesamol-derived silyl aryl triflate A5-1, with benzannulated β-ketoester A5-2, 
resulting in direct access of the tetracyclic core A5-3 (Scheme A5.1). The synthesis was 
completed in 11 additional steps. Subsequent to this work, the benzannulated 
macrolactone (–)-curularin was completed in 6 steps from known compounds (Scheme 
A5.2). Lactone A5-9 was prepared via ring-expansive acyl-alkylation from 
unsymmetrical aryne precursor A5-5 and chiral 10-membered lactone A5-7. 
Debenzylation revealed the resorcinol core, completing the total synthesis. These two 
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syntheses highlight the utility of acyl-alkylation and its ability to rapidly prepare complex 
benzannulated motifs within the context of natural product total synthesis.  
 
Scheme A5.1. Total synthesis of (+)-amurensinine (A5-5). 
 
 
Scheme 2. Total synthesis of (–)-curvularin (A5-10). 
 
 
 
 
  
O
O
OMe
OMe
EtO2C
O
TMS
OTf
CsF
MeCN, 80 °C
(57% yield)
O
O
OMe
OMe
O
EtO2C
1. L-Selectride, THF, –78 °C
2. LiAlH4, THF, 0 °C
3. TIPSCl, imidazole, DMF
         (85% yield, 3 steps)
O
O
OMe
OMe
HO
TIPSO
Pd(sparteine)Cl2 (20 mol%)
(–)-sparteine (20 mol%)
Cs2CO3, O2 (1 atm)
2-methyl-2-butene (20 mol%)
CHCl3, 23 °C, 82 h
(47% yield, > 99% ee, s > 47)
O
O
OMe
OMe
HO
TIPSO
O
O
OMe
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N Me
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OTf
O
O
O
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MeCN, 80 °C
(30% yield)
BnO
BnO
O
O
O
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THF, MeOH
(60% yield)
HO
HO
O
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O
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2
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A5.2 The Development of the Ring Expansive Acyl-Alkyation of Arynes with 
Heterocyclic β-ketoesters 
 
Thus far only fused carbocycles and lactones have been reported as products of 
this ring expansive acyl-alkylation methodology. An investigation utilizing this 
methodology to form benzannulated heterocyclic frameworks had not been pursued.  
We hoped to expand the methodology to heterocyclic β-ketoesters to prepare 
benzannulated heterocycles, providing a convergent, single-step strategy to synthesize a 
variety of important structural motifs including benzazepine derivatives (A5-16, A5-17 
and A5-20), benzoxypines derivatives (A5-18 and A5-19), as well as more challenging 
larger rings (A5-21 and A5-22) (Scheme A5.3). These heterocycles are found in the cores 
of many biologically active natural products. In particular, benzazepine derivatives are a 
scaffold within many important pharmaceuticals such as galantamine (A5-11), a 
treatment for Alzheimer’s disease, and fenoldopam (A5-12), an antihypertensive agent 
(Figure A5.1). 3 , 4  By developing reaction conditions to prepare the cores of these 
important molecules, we would be able to rapidly access complex intermediates, 
providing a more convergent approach to these compounds.  
 
Figure A5.1. Benzannulated heterocycles in biologically active compounds. 
 
 
 
  
NH
Cl
HO
HO
HO
N
O
OH
MeO
Fendolopam Galantamine
A5-12A5-11
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Scheme A5.3. Proposed products of ring expansive acyl-alkylation of arynes. 
 
 
 
 We choose β-ketoester A5-23 on which to optimize our ring-expansive acyl-
alkylation. While less prevalent in natural products and pharmaceuticals it does not 
require a protecting group, thereby simplifying optimization. We began our development 
by replicating the previously reported conditions of Tambar and co-workers (Scheme 
A5.4). This lead to a 2 to 1 mixture of acyl alkylated product A5-24 and α-arylated 
product A5-25 in 48% combined yield.  
 
Scheme A5.4. The acyl-alkylation of benzyne with β-ketoester A5-23. 
 
 
 
 We next examined the effect of varying the fluoride source on the reaction (Table 
A5.1, entries 1–3). Both TBAT and KF/18-Crown-6 gave higher yields of our desired 
acyl-alkylated product. Interestingly, we saw no undesired α-arylated β-ketoester. 
Increasing the temperature to 40 ºC had a positive effect on the yield (Table A5.1, entry 
O
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4–5). However at higher temperature, we observed a decrease in yield. Extended reaction 
times also led to lower yields (Table A5.1, entries 6–7). This is most likely due to over 
arylation at either of the two α-carbons of our acyl-alkylated product. However, 
decreasing equivalents of fluoride source or aryne precursor had a deleterious effect on 
the yield. 
 
Table A5.1. Optimization of the ring-expansive acyl-alkylation of arynes. 
 
 
 During our investigation of any potential side reactions, we hoped to rule out any 
elimination pathways. To probe this possibility, we separately subjected β-ketoester A5-
23 and benzoxapene A5-24 to the reaction conditions. Gratifyingly, both compounds 
were stable to these conditions and were recovered in near quantitative yields (Scheme 
A5.5). 
 
  
Solvent
THF
MeCN
THF
THF
THF
THF
THF
THF
26  :  32
1  :  0
2  :  1
1  :  0
2  :  1
3  :  1
5  :  1
1  :  0
1  :  0
TMS
OTf
O
O
OO
A5-24 A5-25
O
OO
O
OO
OMe
Ph
OMe
2 A5-23
fluoride source
*isolated yield. Conditions: 0.33 mmol 2, 0.26 mmol A5-23, 0.67 mmol fluoride source, 2.5 mL solvent
KF/18-Crown-6 (1.5 equiv)
KF/18-crown-6
KF/18-crown-6
KF/18-crown-6
Fluoride Source
28
22
63
46
54
46
48
46
% yield*
20
20
20
40
40
20
80
20
Temperature (°C)
2.0
3.0
16
3.0
0.5
3.0
0.5
1.0
Time (h)
CsF
TBAT
TBAT
TBAT
8
7
4
1
Entry
2
3
5
6
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Scheme A5.5. Potential unproductive side reactions of ring-expansive acyl alkylation 
 
 
 
 Similarly, changes in solvent did not improve yields (Table A5.2). We were 
limited to ethereal solvents due to the solubility restrictions of our fluoride source, 
KF/18-Crown-6. In reactions that used any non-ethereal solvents, we were only able to 
isolate starting material. The use of a pregenerated enolate of our β-ketoester using 
sodium hydride or potassium tert-butoxide resulted in recovery of starting material.  
 
Table A5.2. Solvent effects on ring-expansive acyl-alkylation. 
 
 
 
  
KF (3 equiv), 18-Crown-6 (3 equiv)
THF, 20 ºC, 1 h
complete recovery of s.m.
O
O
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OH
O
OO
O
OO
OMe
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O
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O
OH
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A5-24 A5-27
not observed
KF (3 equiv), 18-Crown-6 (3 equiv)
THF, 20 ºC, 1 h
complete recovery of s.m.
Entry
1
2
3
4
5
Solvent
dioxane
diethyl Ether
dimethyloxyethane
TBME
2-methyl THF
Time (h)
1
24
0.33
24
2
% Yield
16
25
30
9
46
*
Conditions: 2 (1.25 equiv), A5-23 (1.00 equiv), KF/18-Crown-6 (3.0 equiv)
*isolated yield
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A5.3 Future Directions 
 
 We will expand this methodology to other heterocyclic β-keto esters, includes 6-, 
7- and 8-membered rings. Nitrogen-bearing heterocycles provide the opportunity to 
attenuate the nucleophilicity of the heteroatom through the introduction of a protection 
groups. We hope this will bring about synthetically useful yields which could eventually 
be applied to one of a number of natural products contain these benzanulated  
heterocycles.  
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Appendix 6 
Prepartion of Benzotriazoles via an Aryne-Based Three-Component 
Cross-Coupling 
  
 1H-benzo[d][1,2,3]triazoles (hereafter referred to as benzotriazoles) have been used in a 
variety of applications within the context of organic synthesis.1  The implementation of 
arynes has allowed for facile preparation of this important class of molecules.  Huisgen 
1,3 dipolar cycloadditions, commonly referred to as “click” reactions, have found broad 
application in the synthesis of 1,2,3 triazoles.2  Specifically, organoazides have been 
shown to readily undergo [3+2] cycloaddition with the characteristic strained triple bond 
of aryne without the need of transition metal catalysts. 
 While this reactivity has been known since the early 1960s, in 2008 Larock and 
co-workers reported a simple procedure using alkyl azides and arynes generated in situ 
from the fluoride-induced ortho-elimination of o-(trimethylsilyl)aryl triflates (Scheme 
A6.1, eq 1).  The use of microwave irradiation development has lead to decreased 
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reaction times and improved yields.  The need to pre-generate the organoazides was 
alleviated by a method developed by Beihl and Ankati.  This methodology utilized alkyl 
halides in the presence of sodium azide to followed by [3+2] cycloaddition (Scheme 
A6.1, eq. 2).  
 
Scheme A6-1. Previous preparations of benzotriazoles from benzyne. 
 
Continuing our sustained interest in 3-component couplings, we sought to 
examine the use of electrophiles in the preparation of benzotriazoles.  We initiated our 
studies by attempting to react sodium azide with methyl acrylate and an in situ generated 
aryne. However, this lead to no detectable 3-componant coupling products.  Switching 
our azide source to trimethylsilyl azide lead to a mixture of three benzotriazole products.  
Both 1-phenyl benzotriazole (A6-9) and 3-benzotrizaole-1-yl propionic acid methyl ester 
(A6-9) were prepared in 43% and 41% yield, respectively (Scheme A6.2). Interestingly, 
3-benzotriazole-2-yl propionic acid methyl ester (A6-8) was also isolated in 10% yield, 
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suggesting initial formation of a benzotriazole anion, followed by subsequent 
nucleophilic attack.  However no 2-phenyl benzotriazole (A6-10) was observed.  
A similar mixture of products was observed when the reaction is performed with 
methyl vinyl ketone.  Intriguingly, both 1- and 2-phenyl benzotriazole (A6-9, A6-10) 
were formed (Scheme A6.2).  Finally, when the aryne was used as the electrophile, a 
mixture of 1-phenyl benzoltrizale (A6-9) and 2-phenyl benzotriazole (A6-10) are 
produced in 74% and 18% yield, respectively. 
 
Scheme A6.2. Preparation of benzotriazoles from aryne. 
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 Herein we have report a novel 3-component coupling for the synthesis of N-
substituted benzotriazoles, exploiting the reactivity of benzyne and its propensity to 
undergo dipolar cycloadditions.  
 
Representative Procedure 
Representative procedure: A flame-dried 2 dram vial equipped with a stir bar was 
sequentially charged with 18-crown-6 (194.8 mg, 0.75 mmol, 2.2 equiv.) and potassium 
fluoride (42.8 mg, 0.75 mmol, 2.2 equiv.). The vial was sealed with a septum and 
parafilm. The vial was evacuated and back-filled with N2 3 times. THF (3.3 mL), aryne 
precursor (2) (0.081 mL, 0.34 mmol, 1.0 equiv.), trimethylsilyl azide (0.044 mL, 0.34 
mmol, 1.0 equiv), and methyl vinyl ketone (0.054 mL, 0.68 mmol, 2.0 equiv) were 
sequentially added via syringe. This was stirred at room temperature (23 °C) for 2 hours, 
at which time aryne precursor had been fully consumed, as indicated by TLC (silica, 10% 
hexanes in EtOAc). After 2 hours, the reaction mixture was diluted with 10 mL Et2O. 
This was washed 3 times with 10 mL brine. The aqueous layers were combined and 
extracted with 20 mL Et2O. The organic layers were combined and dried over sodium 
sulfate. This was filtered and the solvent was removed in vacuo to afford a yellow-brown 
oil. The resultant oil was purified on a silica column (1 cm x 20 cm) using a gradient of 
15% to 60% EtOAc in hexanes as an eluent.  
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